<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.2 20190208//EN" "JATS-archivearticle1-mathml3.dtd"> 
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="review-article"><?properties open_access?><?DTDIdentifier.IdentifierValue -//Springer-Verlag//DTD A++ V2.4//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName A++V2.4.dtd?><?SourceDTD.Version 2.4?><?ConverterInfo.XSLTName springer2nlmx2.xsl?><?ConverterInfo.Version 1?><front><journal-meta><journal-id journal-id-type="nlm-ta">Virol J</journal-id><journal-id journal-id-type="iso-abbrev">Virol. J</journal-id><journal-title-group><journal-title>Virology Journal</journal-title></journal-title-group><issn pub-type="epub">1743-422X</issn><publisher><publisher-name>BioMed Central</publisher-name><publisher-loc>London</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">7286216</article-id><article-id pub-id-type="publisher-id">1343</article-id><article-id pub-id-type="doi">10.1186/s12985-020-01343-9</article-id><article-categories><subj-group subj-group-type="heading"><subject>Review</subject></subj-group></article-categories><title-group><article-title>Hepatitis E virus infection during pregnancy</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Wu</surname><given-names>Chunchen</given-names></name><xref ref-type="aff" rid="Aff1"/></contrib><contrib contrib-type="author"><name><surname>Wu</surname><given-names>Xiaoxue</given-names></name><xref ref-type="aff" rid="Aff1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-8912-9921</contrib-id><name><surname>Xia</surname><given-names>Jianbo</given-names></name><address><email>xjb915@126.com</email></address><xref ref-type="aff" rid="Aff1"/></contrib><aff id="Aff1"><institution-wrap><institution-id institution-id-type="GRID">grid.33199.31</institution-id><institution-id institution-id-type="ISNI">0000 0004 0368 7223</institution-id><institution>Department of Laboratory Medicine, Maternal and Child Health Hospital of Hubei Province, Tongji Medical College, </institution><institution>Huazhong University of Science and Technology, </institution></institution-wrap>Wuhan, 430070 People&#x02019;s Republic of China </aff></contrib-group><pub-date pub-type="epub"><day>10</day><month>6</month><year>2020</year></pub-date><pub-date pub-type="pmc-release"><day>10</day><month>6</month><year>2020</year></pub-date><pub-date pub-type="collection"><year>2020</year></pub-date><volume>17</volume><elocation-id>73</elocation-id><history><date date-type="received"><day>30</day><month>1</month><year>2020</year></date><date date-type="accepted"><day>1</day><month>6</month><year>2020</year></date></history><permissions><copyright-statement>&#x000a9; The Author(s) 2020</copyright-statement><license license-type="OpenAccess"><license-p><bold>Open Access</bold>This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>. The Creative Commons Public Domain Dedication waiver (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/publicdomain/zero/1.0/">http://creativecommons.org/publicdomain/zero/1.0/</ext-link>) applies to the data made available in this article, unless otherwise stated in a credit line to the data.</license-p></license></permissions><abstract id="Abs1"><sec><title>Background</title><p id="Par1">Hepatitis E virus (HEV) generally causes self-limiting viral hepatitis. However, in pregnant women, HEV infection can be severe and has been associated with up to 30% mortality in the third trimester. Additionally, HEV infection in pregnancy is also associated with high rates of preterm labor and vertical transmission.</p></sec><sec><title>Main body</title><p id="Par2">HEV is now recognized as a global health problem in both developing and industrialized countries. HEV can be transmitted via the fecal-oral route, zoonotic route, and blood transfusion route. An altered immune status, hormonal levels, and viral factors may be related to the severity of the disease. Currently, no established treatment is available for HEV in pregnant women. A Chinese vaccine has been demonstrated to be protective against HEV in the general population and seems to be safe in pregnancy; however, its safety and efficacy in a large population of pregnant women remain to be determined.</p></sec><sec><title>Conclusion</title><p id="Par3">This review summarizes the current knowledge about HEV infection during pregnancy and focuses on the epidemiology, clinical manifestations, mechanisms underlying severe liver injury, and management and prevention of HEV infection during pregnancy. Considering that HEV infection during pregnancy may result in poor outcomes, screening for and monitoring HEV infection early in pregnancy should be taken into account. In addition, a better understanding of the pathogenesis will help to develop potential treatment strategies targeting HEV infection in pregnancy.</p></sec></abstract><kwd-group xml:lang="en"><title>Keywords</title><kwd>Hepatitis E virus (HEV)</kwd><kwd>Hepatitis E</kwd><kwd>Pregnancy</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#x000a9; The Author(s) 2020</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1"><title>Background</title><p id="Par44">Hepatitis E virus (HEV) is a hepatotropic infectious agent that generally causes self-limiting acute hepatitis in healthy adults and chronic hepatitis in immunocompromised individuals [<xref ref-type="bibr" rid="CR1">1</xref>]. Annually, there are an estimated 20 million HEV infections, 3.3 million symptomatic hepatitis E cases, and 60,000 deaths worldwide [<xref ref-type="bibr" rid="CR1">1</xref>, <xref ref-type="bibr" rid="CR2">2</xref>]. In addition to hepatic manifestations, extrahepatic manifestations, including pancreatitis, neurological symptoms, hematological disorders, glomerulonephritis, and mixed cryoglobulinemia have been associated with HEV infection [<xref ref-type="bibr" rid="CR1">1</xref>, <xref ref-type="bibr" rid="CR3">3</xref>]. HEV is classified into 8 major genotypes, with genotypes 1&#x02013;4 being the predominant strains involved in human infections. Genotypes 1 (HEV-1) and 2 (HEV-2) infect only humans and are transmitted via the fecal-oral route [<xref ref-type="bibr" rid="CR1">1</xref>, <xref ref-type="bibr" rid="CR4">4</xref>], whereas genotypes 3 (HEV-3) and 4 (HEV-4) are zoonotic and are contracted through the consumption of undercooked pork and wild boar meat [<xref ref-type="bibr" rid="CR5">5</xref>]. Although swine are the most commonly implicated source of HEV-3 and HEV-4, other animals including shellfish, deer, and rabbits can serve as a source of infection [<xref ref-type="bibr" rid="CR4">4</xref>, <xref ref-type="bibr" rid="CR6">6</xref>&#x02013;<xref ref-type="bibr" rid="CR9">9</xref>]. Therefore, HEV-1 and HEV-2 are often associated with epidemics in developing countries due to poor hygiene and sanitation. In contrast, HEV-3 and HEV-4 are prevalent in industrialized countries and are associated with sporadic and clustered cases of hepatitis E in these regions [<xref ref-type="bibr" rid="CR1">1</xref>, <xref ref-type="bibr" rid="CR4">4</xref>]. In recent years, the transmission of HEV-3 and HEV-4 through blood transfusions has been increasingly reported in Europe [<xref ref-type="bibr" rid="CR1">1</xref>, <xref ref-type="bibr" rid="CR4">4</xref>, <xref ref-type="bibr" rid="CR10">10</xref>], prompting many countries to consider the screening of blood products for HEV [<xref ref-type="bibr" rid="CR11">11</xref>]. For these reasons, HEV is now recognized as a global health problem in both developing and industrialized countries [<xref ref-type="bibr" rid="CR1">1</xref>, <xref ref-type="bibr" rid="CR12">12</xref>]. Current therapeutics used to treat HEV infection include the nucleoside analog ribavirin and interferon-&#x003b1; (IFN-&#x003b1;). Ribavirin therapy can be fairly efficient in most cases of chronic hepatitis E [<xref ref-type="bibr" rid="CR1">1</xref>, <xref ref-type="bibr" rid="CR2">2</xref>, <xref ref-type="bibr" rid="CR13">13</xref>, <xref ref-type="bibr" rid="CR14">14</xref>]. In some specific situations, interferon has also been used successfully [<xref ref-type="bibr" rid="CR2">2</xref>]. However, until now, there have been no specific direct-acting antiviral agents against HEV, particularly for pregnant women [<xref ref-type="bibr" rid="CR1">1</xref>, <xref ref-type="bibr" rid="CR15">15</xref>]. A recombinant hepatitis E vaccine, HEV 239, has been demonstrated to be well tolerated and effective in the prevention of hepatitis E in China; however, it is currently only approved for use in China and is not yet available elsewhere [<xref ref-type="bibr" rid="CR2">2</xref>, <xref ref-type="bibr" rid="CR16">16</xref>, <xref ref-type="bibr" rid="CR17">17</xref>].</p><p id="Par45">HEV infection can cause fulminant hepatitis failure (FHF), especially in pregnant women, with a mortality rate of up to 30% [<xref ref-type="bibr" rid="CR1">1</xref>, <xref ref-type="bibr" rid="CR18">18</xref>&#x02013;<xref ref-type="bibr" rid="CR20">20</xref>]. In addition, HEV can be vertically transmitted from infected mothers to their infants, with significant perinatal morbidity and mortality [<xref ref-type="bibr" rid="CR20">20</xref>&#x02013;<xref ref-type="bibr" rid="CR22">22</xref>]. Ribavirin and IFN-&#x003b1; are contraindicated in pregnancy because of the risk of teratogenicity [<xref ref-type="bibr" rid="CR23">23</xref>&#x02013;<xref ref-type="bibr" rid="CR25">25</xref>]. Therefore, only supportive care is provided for pregnant women with HEV infection. In this review, we provide a summary of the current knowledge regarding HEV and highlight HEV infection during pregnancy, which has been poorly understood until now and deserves the utmost attention.</p></sec><sec id="Sec2"><title>Main text</title><sec id="Sec3"><title>Molecular virology of HEV</title><p id="Par46">HEV belongs to the family of <italic>Hepeviridae</italic> and is the sole member of the genus <italic>Orthohepevirus</italic>. HEV is icosahedral in shape and can exist in both nonenveloped and enveloped (eHEV) forms, with diameters of approximately 30&#x02009;nm and 40&#x02009;nm, respectively [<xref ref-type="bibr" rid="CR1">1</xref>, <xref ref-type="bibr" rid="CR12">12</xref>]. These two forms of HEV particles may be transmitted via different routes and possess distinct characteristics in the viral life cycle [<xref ref-type="bibr" rid="CR1">1</xref>, <xref ref-type="bibr" rid="CR12">12</xref>]. The HEV genome is a single-stranded, positive-sense, linear RNA that is approximately 7.2&#x02009;kb in length [<xref ref-type="bibr" rid="CR26">26</xref>]. The RNA genome consists of a 5&#x02032; untranslated region (UTR), three open reading frames (ORFs) and a 3&#x02032; UTR. ORF1 comprises approximately 70% of the genome (5109&#x02009;bp) and encodes nonstructural polyproteins, such as methyltransferase (Met), Y-domain (Y), papain-like cysteine protease (PCP) [<xref ref-type="bibr" rid="CR27">27</xref>], hypervariable region (HVR) [<xref ref-type="bibr" rid="CR28">28</xref>], macrodomain (X), RNA helicase (Hel) [<xref ref-type="bibr" rid="CR29">29</xref>, <xref ref-type="bibr" rid="CR30">30</xref>] and RNA-dependent RNA polymerase (RdRp) [<xref ref-type="bibr" rid="CR31">31</xref>, <xref ref-type="bibr" rid="CR32">32</xref>], those are necessary for replication [<xref ref-type="bibr" rid="CR1">1</xref>, <xref ref-type="bibr" rid="CR17">17</xref>, <xref ref-type="bibr" rid="CR33">33</xref>]. ORF2 and ORF3 partially overlap and are translated from a single subgenomic RNA [<xref ref-type="bibr" rid="CR34">34</xref>]. ORF2 encodes both glycosylated ORF2 antigen and viral capsid protein [<xref ref-type="bibr" rid="CR35">35</xref>, <xref ref-type="bibr" rid="CR36">36</xref>]. ORF3 encodes a small multifunctional phosphoprotein that is required for virus egress from cells and proposed to perturb numerous cellular pathways [<xref ref-type="bibr" rid="CR12">12</xref>, <xref ref-type="bibr" rid="CR17">17</xref>] (Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1</xref>).
<fig id="Fig1"><label>Fig. 1</label><caption><p>Schematic description of the hepatitis E virus (HEV) genome and viral proteins. The HEV genome is a single-stranded, positive-sense, linear RNA that is approximately 7.2&#x02009;kb in length. The RNA genome consists of a 5&#x02032; untranslated region (UTR), three open reading frames (ORFs) and a 3&#x02032; UTR. ORF1 comprises approximately 70% of the genome (5109&#x02009;bp) and encodes nonstructural polyproteins, such as methyltransferase (Met), Y-domain (Y), PCP, hypervariable region (HVR), macrodomain (X), RNA helicase (Hel) and RNA-dependent RNA polymerase (RdRp), which are necessary for replication. ORF2 and ORF3 partially overlap and are translated from a single subgenomic RNA that is approximately 2.2&#x02009;kb in length. ORF2 encodes a viral capsid protein that is required for viral entry, assembly and immunogenicity. ORF3 encodes a small multifunctional phosphoprotein (MFP) that is required for virus egress from cells and proposed to perturb numerous cellular pathways</p></caption><graphic xlink:href="12985_2020_1343_Fig1_HTML" id="MO1"/></fig></p><p id="Par47">The study of HEV replication has been limited to efficient cell culture systems, and replication within the host is not yet fully understood. The HEV capsid protein is believed to be essential for binding to an unknown cellular receptor to initiate viral entry [<xref ref-type="bibr" rid="CR37">37</xref>]. The eHEV may have a distinct mechanism of viral entry, considering that it is enveloped and capsid protein is not exposed on the surface [<xref ref-type="bibr" rid="CR38">38</xref>]. After entering the target cell, the virus is uncoated, and the viral RNA genome is released into the cytoplasm. Following this, viral nonstructural proteins are translated from ORF1 [<xref ref-type="bibr" rid="CR39">39</xref>]. A negative-sense intermediate RNA is synthesized based on the positive-sense viral RNA genome with the help of RdRp; this product, in turn, serves as a template to produce 7.2-kb positive-sense progeny viral RNA as well as 2.2-kb subgenomic RNA [<xref ref-type="bibr" rid="CR31">31</xref>, <xref ref-type="bibr" rid="CR40">40</xref>]. Subsequently, the subgenomic RNA acts as a template to translate capsid proteins and phosphoproteins [<xref ref-type="bibr" rid="CR37">37</xref>]. The genomic RNA is contained within the capsid proteins, and new virions are generated and finally released by mechanisms still unclear [<xref ref-type="bibr" rid="CR17">17</xref>, <xref ref-type="bibr" rid="CR41">41</xref>].</p></sec><sec id="Sec4"><title>Epidemiology of HEV infection in pregnancy</title><p id="Par48">HEV infection is associated with high incidence and mortality (principally due to fulminant hepatitis) in pregnant women according to the majority of clinical studies and case reports from developing countries [<xref ref-type="bibr" rid="CR1">1</xref>, <xref ref-type="bibr" rid="CR4">4</xref>, <xref ref-type="bibr" rid="CR10">10</xref>, <xref ref-type="bibr" rid="CR42">42</xref>]. A prospective field study carried out by Khuroo et al. showed that hepatitis E developed in 36 (17.3%) of 208 pregnant women, as compared to 71 (2.1%) of 3350 nonpregnant women and 107 (2.8%) of 3822 men. FHF developed in 8 (22.2%) of the 36 pregnant women with hepatitis E. In contrast, none of the nonpregnant women showed the occurrence of fulminant hepatic failure [<xref ref-type="bibr" rid="CR43">43</xref>]. For the first time, this study revealed that the incidence of hepatitis E and fulminant rates were higher in pregnant women than nonpregnant women and men. In another study, HEV infection was observed in 57.5 and 46% of pregnant and nonpregnant women, respectively. Moreover, 58% of the HEV-infected pregnant women developed FHF. The mortality rate was highest (56%) among HEV-infected FHF cases during the third trimester of pregnancy [<xref ref-type="bibr" rid="CR44">44</xref>]. This study indicated that pregnant women, especially those in the second and third trimesters, are more commonly affected during epidemics than the general population [<xref ref-type="bibr" rid="CR42">42</xref>]. Various studies from different regions of the Indian subcontinent reported that the prevalence rate of HEV in acute viral hepatitis during pregnancy ranged from 58 to 86% [<xref ref-type="bibr" rid="CR44">44</xref>&#x02013;<xref ref-type="bibr" rid="CR46">46</xref>]. HEV infection can result in up to 30% mortality among pregnant women in their third trimester [<xref ref-type="bibr" rid="CR1">1</xref>, <xref ref-type="bibr" rid="CR18">18</xref>&#x02013;<xref ref-type="bibr" rid="CR20">20</xref>]. HEV-1 and HEV-2 are likely responsible for most of the HEV outbreaks because they are the most prevalent genotypes in developing countries [<xref ref-type="bibr" rid="CR10">10</xref>, <xref ref-type="bibr" rid="CR42">42</xref>]. Additionally, HEV infection in pregnancy is also associated with high rates of preterm labor and vertical transmission [<xref ref-type="bibr" rid="CR10">10</xref>, <xref ref-type="bibr" rid="CR47">47</xref>, <xref ref-type="bibr" rid="CR48">48</xref>]. The frequent occurrence of other complications, such as disseminated intravascular coagulation (DIC), is also associated with HEV infection in pregnant women [<xref ref-type="bibr" rid="CR4">4</xref>]. For industrialized countries, there are few reported cases in pregnant women [<xref ref-type="bibr" rid="CR49">49</xref>&#x02013;<xref ref-type="bibr" rid="CR51">51</xref>]; HEV-3 and HEV-4 are associated with these cases [<xref ref-type="bibr" rid="CR50">50</xref>, <xref ref-type="bibr" rid="CR51">51</xref>]. Unlike HEV-1 and HEV-2, HEV-3 and HEV-4 do not appear to cause fatal infections with fulminant hepatitis in pregnant women [<xref ref-type="bibr" rid="CR10">10</xref>, <xref ref-type="bibr" rid="CR49">49</xref>]. However, considering that the limitation of these studies was the small number of cases, other studies are needed to clarify this result.</p><p id="Par49">China is an epidemic area for HEV, and HEV-4 is currently the dominant cause of hepatitis E [<xref ref-type="bibr" rid="CR52">52</xref>, <xref ref-type="bibr" rid="CR53">53</xref>]. HEV infection has considerable potential for transmission in pregnant women in China. It was estimated that the positivity rates of anti-HEV IgM and anti-HEV IgG were 2.6 and 16.2%, respectively, in pregnant women from Shandong Province and 0.6 and 11.1%, respectively, in pregnant women from Jiangsu Province, China [<xref ref-type="bibr" rid="CR54">54</xref>, <xref ref-type="bibr" rid="CR55">55</xref>]. In contrast, the positivity rate of anti-HEV IgM was 2.56% in pregnant women in Yunnan Province [<xref ref-type="bibr" rid="CR56">56</xref>]. These results may reflect the varied seroprevalence of HEV infection in different areas of China. In addition, anti-HEV IgM seropositivity occurs first and persists for 3&#x02013;5&#x02009;months after the initial disease onset [<xref ref-type="bibr" rid="CR57">57</xref>, <xref ref-type="bibr" rid="CR58">58</xref>]. Shortly after the appearance of IgM, IgG antibodies develop seropositivity and persist throughout the acute and convalescent phases, maintaining high levels for a year [<xref ref-type="bibr" rid="CR59">59</xref>]. Therefore, seroprevalence to HEV in pregnant women does not necessarily reflect current HEV-positivity and may result from infection and clearance prior to becoming pregnant. Furthermore, besides the factors related to sex, age structure, and sampling errors, the differences in the specificity and sensitivity of HEV detection attributable to different laboratory diagnostic techniques should also be considered [<xref ref-type="bibr" rid="CR55">55</xref>, <xref ref-type="bibr" rid="CR60">60</xref>]. A recent study among pregnant women in Qinhuangdao, China, showed that the positivity rates of anti-HEV IgM and/or anti-HEV IgG were significantly higher in the third trimester than in the first and second trimesters [<xref ref-type="bibr" rid="CR61">61</xref>], consistent with previous reports. Among these pregnant women, the HEV strain exclusively identified in those with a history of HEV infection was HEV-4 [<xref ref-type="bibr" rid="CR61">61</xref>], which seemingly coincides with the fact that HEV-4 is now the most prevalent strain in China. However, considering that HEV-1 and HEV-3 have also been reported in China [<xref ref-type="bibr" rid="CR62">62</xref>, <xref ref-type="bibr" rid="CR63">63</xref>], more studies are needed to clarify the HEV genotypes prevalent among pregnant women in China and the correlation between HEV genotypes and maternal and fetal outcomes.</p><p id="Par50">The combination of other virus infections with HEV infection may enhance the mortality rate. It is estimated that in patients suffering from chronic liver disease (e.g., hepatitis B virus (HBV) infection), these infections often progress to liver failure, with a mortality rate of 27% [<xref ref-type="bibr" rid="CR64">64</xref>, <xref ref-type="bibr" rid="CR65">65</xref>]. Our unpublished data suggested that there were increased rates of other virus infections in both anti-HEV IgM- and anti-HEV IgG-positive pregnant women. In pregnant women with chronic hepatitis C virus (HCV) coinfection, a marked increase in anti-HEV IgG seropositivity and a significant worsening of the biochemical liver indices have been observed [<xref ref-type="bibr" rid="CR66">66</xref>]. Therefore, more efforts are needed to investigate the epidemiology of other virus infections combined with HEV infection in pregnancy.</p></sec><sec id="Sec5"><title>Clinical manifestations</title><sec id="Sec6"><title>Acute hepatitis E</title><p id="Par51">According to previous data, the clinical manifestations of HEV infection are different, varying from asymptomatic to fulminant hepatic failure. HEV usually causes an acute self-limiting hepatitis. The prodromal phase lasts up to 1 week, and the symptoms may be nonspecific, such as malaise, fever, joint pain, nausea, and vomiting. Subsequently, a series of typical symptoms related to acute icteric hepatitis, including jaundice, darkened urine, and pale stools may occur, similar to those seen in HAV infection [<xref ref-type="bibr" rid="CR67">67</xref>]. However, compared with HAV, patients with HEV are known to have prolonged cholestasis [<xref ref-type="bibr" rid="CR68">68</xref>]. Mansuy et al. [<xref ref-type="bibr" rid="CR69">69</xref>] studied 62 confirmed cases of acute hepatitis E over a 5&#x02009;year period in south-west France and found that about 60% of patients became jaundiced. In fact, the jaundice rate of acute HEV infection is likely much lower given that most cases are not recognized or diagnosed. Serum alanine aminotransferase (ALT) and aspartate aminotransferase (AST) levels are markedly elevated, and bilirubin levels can also rise [<xref ref-type="bibr" rid="CR10">10</xref>, <xref ref-type="bibr" rid="CR70">70</xref>]. In immunocompetent individuals, the infection and symptoms typically resolve spontaneously within 4&#x02013;6&#x02009;weeks [<xref ref-type="bibr" rid="CR71">71</xref>]. Compared to nonpregnant women, clinical features do not differ in pregnant women at first [<xref ref-type="bibr" rid="CR72">72</xref>]. However, acute liver failure can develop rapidly in patients with HEV infection during pregnancy. Several complications of fulminant hepatic failure, including cerebral edema, DIC, and encephalopathy, appear to occur at a higher rate [<xref ref-type="bibr" rid="CR18">18</xref>]. Hepatic encephalopathy is the most common cause of death among these patients [<xref ref-type="bibr" rid="CR72">72</xref>, <xref ref-type="bibr" rid="CR73">73</xref>]. Besides maternal mortality, fetal mortality can occur, especially during the third trimester. Preterm delivery, low birth weight, and stillbirth of the fetus or newborn have also been observed in these patients [<xref ref-type="bibr" rid="CR72">72</xref>].</p></sec><sec id="Sec7"><title>Chronic hepatitis E</title><p id="Par52">Chronic HEV infection is defined as an HEV viremia for more than 3 months [<xref ref-type="bibr" rid="CR74">74</xref>]. In immunocompromised individuals who receive immunosuppressive therapy following solid organ transplantation or stem cell transplantation [<xref ref-type="bibr" rid="CR75">75</xref>&#x02013;<xref ref-type="bibr" rid="CR77">77</xref>] and those with human immunodeficiency virus (HIV) infection [<xref ref-type="bibr" rid="CR78">78</xref>, <xref ref-type="bibr" rid="CR79">79</xref>] or with hematological malignancy [<xref ref-type="bibr" rid="CR80">80</xref>&#x02013;<xref ref-type="bibr" rid="CR82">82</xref>], chronic HEV infection may develop. This disease course of chronic infection has mainly been reported for HEV-3 and 4, leading to life-threatening liver fibrosis and cirrhosis [<xref ref-type="bibr" rid="CR75">75</xref>, <xref ref-type="bibr" rid="CR80">80</xref>, <xref ref-type="bibr" rid="CR83">83</xref>&#x02013;<xref ref-type="bibr" rid="CR85">85</xref>]. It has been reported that HEV-3 can cause acute hepatitis E in pregnant women, followed by rapid clearance without any signs of severe courses [<xref ref-type="bibr" rid="CR50">50</xref>, <xref ref-type="bibr" rid="CR51">51</xref>].</p></sec><sec id="Sec8"><title>Extrahepatic manifestations of hepatitis E</title><p id="Par53">Acute or chronic or previous HEV infection can cause extrahepatic manifestations [<xref ref-type="bibr" rid="CR86">86</xref>, <xref ref-type="bibr" rid="CR87">87</xref>], which include a range of neurological symptoms and impaired kidney function associated with cryoglobulinemia [<xref ref-type="bibr" rid="CR84">84</xref>, <xref ref-type="bibr" rid="CR88">88</xref>]. Other extrahepatic manifestations documented in the literature include acute thyroiditis [<xref ref-type="bibr" rid="CR89">89</xref>], thrombocytopenia [<xref ref-type="bibr" rid="CR90">90</xref>], and acute pancreatitis [<xref ref-type="bibr" rid="CR91">91</xref>]. However, it remains uncertain whether extrahepatic manifestations of HEV are attributed to direct infection of extrahepatic tissues or cross-reactive immune responses. As of now, the molecular mechanism of extrahepatic tissue injury caused by HEV infection is unclear, and the roles of pathogenic genotypes and immune function remain to be identified.</p></sec></sec><sec id="Sec9"><title>Mechanisms underlying severe liver injury due to HEV infection during pregnancy</title><p id="Par54">The mechanisms of severe liver injury due to HEV infection in pregnant women are unknown. According to previous studies, the unique characteristics of pregnant women, such as altered immunity, hormone levels, and viral factors, such as HEV genome heterogeneity and variants, may be related to the severity of the disease [<xref ref-type="bibr" rid="CR19">19</xref>, <xref ref-type="bibr" rid="CR42">42</xref>] (Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2</xref>).
<fig id="Fig2"><label>Fig. 2</label><caption><p>Mechanisms underlying severe liver injury due to HEV infection in pregnancy. The altered status of immunity, hormone levels and viral factors may be related to the severity of the disease. Viral factors include HEV genome heterogeneity and variants, as well as viral proteins, such as MFP, encoded by HEV ORF3, may be associated with the severity of the disease. Host immune factors, such as CD8+ T cells, NK and NKT cells, may be involved in the pathogenicity of HEV during pregnancy. In addition, some cytokines, such as TNF-&#x003b1;, IL-6, IFN-&#x003b3;, and TGF-&#x003b2;1, may also be involved in this process. The dramatically elevated levels of hormonal factors, including progesterone, estrogen and HCG, in pregnancy may also contribute to liver injury. Other host factors, such as nutritional status, may also influence the severity of HEV infection in pregnant women</p></caption><graphic xlink:href="12985_2020_1343_Fig2_HTML" id="MO2"/></fig></p><sec id="Sec10"><title>Immunity</title><p id="Par55">During pregnancy, the maternal immune system must balance the need to maintain robust immune reactivity to protect both the mother and fetus from invading pathogens and tolerate highly immunogenic paternal alloantigens to sustain fetal integrity [<xref ref-type="bibr" rid="CR92">92</xref>]. Therefore, the immune alterations that occur during pregnancy are considerably complex. A longitudinal study showed that compared to the postpartum period, the number and activity of natural killer (NK) and T cells decrease during pregnancy, while monocytes, granulocytes, and dendritic cells (DCs) increase in peripheral blood during pregnancy [<xref ref-type="bibr" rid="CR93">93</xref>], suggesting that adaptive immune responses are weakened, while innate immune responses are strengthened during pregnancy [<xref ref-type="bibr" rid="CR93">93</xref>&#x02013;<xref ref-type="bibr" rid="CR95">95</xref>]. Additionally, a shift from a Th1-dominated immune response to a Th2-dominated response, known as a &#x0201c;Th2 bias&#x0201d;, during pregnancy has been proposed [<xref ref-type="bibr" rid="CR96">96</xref>]. Th2 cells stimulate B lymphocytes and increase antibody production but inhibit the cytotoxic T lymphocyte response, leading to impaired cell-mediated immunity [<xref ref-type="bibr" rid="CR96">96</xref>]. In view of these points, the pregnant mother and the fetus may be protected from susceptibility to initial infection. However, once infected, pathogen clearance may be impaired, resulting in increased severity of the disease, especially for infections such as influenza, cytomegalovirus (CMV), severe acute respiratory syndrome (SARS), varicella- zoster, malaria, and herpes simplex virus (HSV) infection, in which cell-mediated immunity is important [<xref ref-type="bibr" rid="CR93">93</xref>, <xref ref-type="bibr" rid="CR97">97</xref>]. Regarding the regulation of cellular immunity during pregnancy, the Th1 / Th2 paradigm has been expanded into the Th1 / Th2 / Th17 and Treg cell paradigm to better explain the mechanism by which the fetus is not rejected by maternal immune cells [<xref ref-type="bibr" rid="CR98">98</xref>]. The function of effector T cells, such as Th1, Th2, and Th17 cells, is regulated by CD4+ CD25+ Treg cells [<xref ref-type="bibr" rid="CR99">99</xref>, <xref ref-type="bibr" rid="CR100">100</xref>]. Therefore, although the Th1/Th2 paradigm is useful, a host of important immune elements operates during pregnancy to regulate systemic Th1 responses, including higher frequencies of T regulatory cells.</p><p id="Par56">The immunological mechanisms underlying severe liver injury due to HEV infection in pregnancy are not yet well understood. It has been reported that liver injury resulting from HEV in the general population is due to immune-activated CD8, NK and NKT cells in the liver as well as in peripheral circulation [<xref ref-type="bibr" rid="CR86">86</xref>, <xref ref-type="bibr" rid="CR101">101</xref>&#x02013;<xref ref-type="bibr" rid="CR103">103</xref>]. In HEV-positive pregnant patients with FHF, CD4&#x02009;+&#x02009;T cell counts were lower, CD8&#x02009;+&#x02009;T cell counts were higher and CD4+/CD8+ ratios were significantly lower than those in HEV-negative pregnant women or in controls with FHF [<xref ref-type="bibr" rid="CR104">104</xref>]. However, the role of NK and NKT cells in the pathogenesis of FHF in pregnant women remains unknown. Moreover, although Th2 bias was confirmed to exist in pregnant women with HEV infection, its effect on the severity of HEV infection is unknown [<xref ref-type="bibr" rid="CR86">86</xref>].</p><p id="Par57">Impaired monocyte-macrophage functions and defective Toll-like receptor signaling have been found in HEV-infected pregnant women with ALF, suggesting that inadequate triggers for innate immune responses may contribute to the development and severity of liver injury due to HEV infection in pregnancy [<xref ref-type="bibr" rid="CR86">86</xref>, <xref ref-type="bibr" rid="CR105">105</xref>]. In pregnant patients with FHF due to HEV, the DNA-binding activity of NF-&#x003ba;B was much higher than those in nonpregnant women and women with acute viral hepatitis (AVH) without FHF. An analysis of the NF-&#x003ba;B complex showed that the expression of p65 was completely absent or dramatically decreased in these patients [<xref ref-type="bibr" rid="CR106">106</xref>]. High concentrations of cytokines, including TNF-&#x003b1;, IL-6, IFN-&#x003b3;, and TGF-&#x003b2;1, may also be related to adverse pregnancy outcomes [<xref ref-type="bibr" rid="CR107">107</xref>]. Therefore, the abnormal expression or functioning of immunological factors may cause deregulated immunity and severe liver damage in the context of HEV infection. Other host factors, such as nutritional status, including micronutrient deficiencies and the lack of folic acid, may also influence the immune response to HEV infection in pregnant women [<xref ref-type="bibr" rid="CR108">108</xref>&#x02013;<xref ref-type="bibr" rid="CR111">111</xref>].</p></sec><sec id="Sec11"><title>Hormonal factors</title><p id="Par58">As pregnancy progresses, the levels of hormonal factors, such as progesterone, estrogen and human chorionic gonadotropin (HCG), change dramatically and are considerably higher than at any other time [<xref ref-type="bibr" rid="CR96">96</xref>, <xref ref-type="bibr" rid="CR112">112</xref>, <xref ref-type="bibr" rid="CR113">113</xref>], potentially also contributing to poor outcomes. The levels of the three hormonal factors were found to be higher in HEV-positive pregnant FHF patients than in HEV-negative patients or controls [<xref ref-type="bibr" rid="CR104">104</xref>]. Increased estradiol in the serum of HEV-infected pregnant women promoted viral replication [<xref ref-type="bibr" rid="CR114">114</xref>, <xref ref-type="bibr" rid="CR115">115</xref>], which may be associated with poor outcomes [<xref ref-type="bibr" rid="CR86">86</xref>]. In addition, a high level of estrogen was found to be related to preterm delivery, low birth weight infants and fetal mortality through placental dysfunction in pregnant women with HEV infection [<xref ref-type="bibr" rid="CR116">116</xref>].</p><p id="Par59">Many studies have shown that hormonal factors play an important role in the modulation of the immune system. For example, high levels of progesterone and estrogen can alter the balance between Th1 and Th2 responses [<xref ref-type="bibr" rid="CR96">96</xref>]. Estrogen also directly reduces CD8 T cell cytotoxicity [<xref ref-type="bibr" rid="CR94">94</xref>]. Moreover, estrogen can alter B cell survival and activation as well as suppress B cell lymphopoiesis during pregnancy [<xref ref-type="bibr" rid="CR94">94</xref>]. Progesterone receptor (PR) gene mutations (PROGINS) were reported to be associated with the incidence of FHF in pregnancy. Progesterone-induced blocking factor (PIBF), which exerts antiabortive activity by inhibiting NK cells and influencing both humoral and cellular immune responses, along with PR was found to be decreased in women with FHF [<xref ref-type="bibr" rid="CR86">86</xref>, <xref ref-type="bibr" rid="CR117">117</xref>].</p></sec><sec id="Sec12"><title>Viral factors</title><sec id="FPar1"><title>Genome heterogeneity and HEV variants</title><p id="Par60">According to the epidemiology of HEV infection, there were variations in the rates of maternal morbidity and mortality among the different HEV genotypes. According to current data, HEV-1 and HEV-2 are the most common genotypes associated with morbidity and mortality in pregnancy. In contrast, the association of increased incidence and severity of hepatitis E in pregnant women infected with HEV-1 or HEV-2 is not observed for HEV-3 and HEV-4 [<xref ref-type="bibr" rid="CR10">10</xref>, <xref ref-type="bibr" rid="CR49">49</xref>&#x02013;<xref ref-type="bibr" rid="CR51">51</xref>, <xref ref-type="bibr" rid="CR118">118</xref>, <xref ref-type="bibr" rid="CR119">119</xref>]. A recent study in an ex vivo model using organ culture from the maternal decidua and fetal placenta demonstrated that HEV-1 replicated more efficiently at the maternal-fetal interface, produced more infectious progeny virions, and caused more severe tissue alterations than HEV-3 [<xref ref-type="bibr" rid="CR120">120</xref>]. These results indicate that the HEV genotype may play an important role in the pathogenicity of HEV, especially during pregnancy. However, due to the lack of appropriate in vivo and in vitro experimental models and the difficulty of propagating the virus in vitro, no studies have systematically compared the susceptibility, infectivity, replication ability, and virulence of the different HEV genotypes.</p><p id="Par61">In addition, genetic HEV variants have shown to affect viral morphogenesis, pathogenesis, clinical outcomes, and antiviral resistance [<xref ref-type="bibr" rid="CR121">121</xref>&#x02013;<xref ref-type="bibr" rid="CR123">123</xref>]. However, it remains unknown whether these variants have been linked to morbidity/mortality in pregnancy, and needs further study.</p></sec><sec id="FPar2"><title>Viral proteins</title><p id="Par62">The detailed functions of the viral proteins in HEV infection and pathogenesis remain unclear. The D29N and V27A mutations in ORF1-encoded Met were significantly associated with poor outcomes in acute liver failure patients [<xref ref-type="bibr" rid="CR124">124</xref>]. V239A mutation in ORF1-encoded Hel identified in severe hepatitis cases might be associated with increased virulence of the genotype 3 virus [<xref ref-type="bibr" rid="CR125">125</xref>]. ORF1-encoded macrodomain can inhibit the phosphorylation/activation of interferon regulatory factor 3 (IRF-3), thus possibly combating the host antiviral response [<xref ref-type="bibr" rid="CR126">126</xref>]. In addition, the macrodomain can interact with the light chain subunit of human ferritin and inhibit its secretion, suggesting its possible role in suppressing the innate immune response [<xref ref-type="bibr" rid="CR127">127</xref>]. These reports suggest the possible involvement of ORF1-encoded proteins in determining the outcome of HEV infections. Besides ORF1, the ORF2-encoded capsid protein can also antagonize IFN induction by blocking the phosphorylation of IRF-3 via interaction with the multiprotein complex consisting of mitochondrial antiviral-signaling protein (MAVS), TANK-binding kinase 1 (TBK1), and IRF3 [<xref ref-type="bibr" rid="CR128">128</xref>]. Recently published data showed that another ORF2-encoded protein, which is glycosylated and can be secreted into the patient serum or supernatants of HEV-infected cell culture in the form of a dimer, inhibits antibody-mediated neutralization and thus may lead to immune escape [<xref ref-type="bibr" rid="CR35">35</xref>]. These studies revealed that ORF2-encoded proteins might be involved in the interference and/or evasion of the hosts&#x02019; innate immunity. In addition, some studies have shown that capsid protein may play a role in facilitating HEV survival or replication in infected hepatocytes. For example, capsid protein inhibits cellular NF-&#x003ba;B activity by blocking ubiquitin-mediated proteasomal degradation of I&#x003ba;B&#x003b1; in human hepatoma cells, presumably enhancing survival of HEV-infected hepatocytes [<xref ref-type="bibr" rid="CR129">129</xref>]. Moreover, the capsid protein activates the pro-apoptotic gene CHOP and anti-apoptotic heat shock proteins [<xref ref-type="bibr" rid="CR130">130</xref>]. HEV ORF3 is proposed to be responsible for HEV-associated coagulopathy. ORF3-encoded proteins may interact with several clotting-related pathways, leading to an imbalance in coagulation and fibrinolysis [<xref ref-type="bibr" rid="CR131">131</xref>].</p></sec></sec></sec><sec id="Sec13"><title>Management of HEV infection during pregnancy</title><p id="Par63">Ribavirin was classified in Pregnancy Category X by the United States Food and Drug Administration (FDA) because of its embryocidal and teratogenic effects in animals [<xref ref-type="bibr" rid="CR25">25</xref>, <xref ref-type="bibr" rid="CR132">132</xref>, <xref ref-type="bibr" rid="CR133">133</xref>] Thus, ribavirin is not recommended for use in pregnant women. IFN-&#x003b1; was classified in Pregnancy Category C by the FDA, taking into account its abortifacient effect in animals and adverse effects [<xref ref-type="bibr" rid="CR133">133</xref>]. Therefore, IFN-&#x003b1; was not recommended to be administered to pregnant women [<xref ref-type="bibr" rid="CR23">23</xref>, <xref ref-type="bibr" rid="CR24">24</xref>]. Recently, sofosbuvir showed antiviral activity against HEV both in vitro and in vivo and thus may be a promising antiviral drug against HEV in pregnancy as a pregnancy category B drug [<xref ref-type="bibr" rid="CR134">134</xref>, <xref ref-type="bibr" rid="CR135">135</xref>]. As far as other antiviral candidates are concerned, interferon &#x003bb;1&#x02013;3 was shown to inhibit HEV replication [<xref ref-type="bibr" rid="CR136">136</xref>, <xref ref-type="bibr" rid="CR137">137</xref>]. The antisense peptide-conjugated morpholino oligomers (PPMO) HP1, targeting a highly conserved sequence in the start site region of ORF1, can lead to a significant reduction in the levels of HEV RNA and capsid protein, suggesting its potential as a promising antiviral candidate [<xref ref-type="bibr" rid="CR138">138</xref>]. A recent study showed that nucleoside analogs NITD008, 2&#x02032;-C-methylguanosine (2CMG), and the non-nucleoside inhibitor GPC-N114 can inhibit HEV in cell culture [<xref ref-type="bibr" rid="CR139">139</xref>, <xref ref-type="bibr" rid="CR140">140</xref>]. However, more controlled studies are needed before sofosbuvir can be recommended for HEV infection in pregnancy. For the other antiviral candidates mentioned above, there is a long way to go. Therefore, the management of HEV infection in pregnancy is currently supported by diligent monitoring and intensive care [<xref ref-type="bibr" rid="CR42">42</xref>].</p><p id="Par64">Considering that there is no established treatment available for HEV infection in pregnant women, preventing HEV infection in pregnancy may be the most important management strategy [<xref ref-type="bibr" rid="CR141">141</xref>]. The Chinese vaccine for HEV, HEV 239, has been demonstrated to be protective against both HEV-1 and HEV-4 [<xref ref-type="bibr" rid="CR122">122</xref>, <xref ref-type="bibr" rid="CR142">142</xref>]. In healthy adults, three doses of HEV 239 (30&#x02009;&#x003bc;g of purified recombinant hepatitis E antigen absorbed to 0.8&#x02009;mg of aluminium hydroxide suspended in 0.5&#x02009;mL of buffered saline) were administered intramuscularly at 0, 1, and 6&#x02009;months and 100.0% vaccine efficacy was achieved [<xref ref-type="bibr" rid="CR16">16</xref>]. HEV 239 also seems to be safe in pregnant women [<xref ref-type="bibr" rid="CR143">143</xref>]. In addition, in a rabbit model, two doses of 10&#x02009;&#x003bc;g or 5&#x02009;&#x003bc;g HEV 239 vaccine administered intramuscularly on weeks 0 and 4 not only serve to protect pregnant rabbits from HEV infection but also prevent HEV-related adverse outcomes [<xref ref-type="bibr" rid="CR144">144</xref>]. Although the safety and efficacy of this vaccine in a large population of pregnant women remain to be determined, this vaccine is promising for HEV infection prevention in pregnancy and may thus decrease HEV-associated morbidity and mortality. Besides advocating for studies of HEV 239 vaccination during pregnancy, it would also seem prudent to advocate for vaccination of at-risk women of childbearing age in endemic regions before they become pregnant. Recently, a phase IV trial has been initiated to assess the effectiveness, safety, and immunogenicity of the HEV 239 vaccine in women of childbearing age in rural Bangladesh, where HEV infection is endemic [<xref ref-type="bibr" rid="CR145">145</xref>].</p></sec></sec><sec id="Sec14"><title>Conclusions</title><p id="Par65">HEV infection is not limited to certain developing countries; it is also endemic in many high-income countries and is largely zoonotic in nature. Despite increasing knowledge, many questions regarding HEV, especially HEV infection during pregnancy, remain unanswered. In addition to immune and hormonal factors, genome heterogeneity and HEV variants may be related to the severity of HEV infection in pregnancy. Therefore, it may be important to investigate the prevalent HEV genotypes and their virulence as well as morbidity in pregnancy; this information could be used to develop guidelines for the intervention and management of HEV infection in pregnancy. HEV can be transmitted via blood transfusion. Increasing prevalence rates of HEV in voluntary blood donors (VBDs) and transfusion-associated HEV infections have been reported [<xref ref-type="bibr" rid="CR1">1</xref>, <xref ref-type="bibr" rid="CR4">4</xref>, <xref ref-type="bibr" rid="CR10">10</xref>, <xref ref-type="bibr" rid="CR146">146</xref>]. Therefore, screening donors for HEV RNA may need to be considered.</p><p id="Par66">Considering that HEV infection in pregnant women may progress to fulminant hepatitis, especially in the third trimester, with a high mortality rate, screening for and monitoring HEV infection early in pregnancy should become a focus. In addition, it is also necessary to inform pregnant women of the potential effects of HEV on the fetus; they should be advised to avoid eating and drinking contaminated food and water to prevent possible HEV exposure. An HEV vaccine may hold great promise for reducing HEV-associated mortality in pregnant women. Finally, there is also a substantial need for novel therapies to treat HEV in pregnancy.</p></sec></body><back><glossary><title>Abbreviations</title><def-list><def-item><term>HEV</term><def><p id="Par4">Hepatitis E virus</p></def></def-item><def-item><term>HEV-1</term><def><p id="Par5">Genotypes 1</p></def></def-item><def-item><term>HEV-2</term><def><p id="Par6">Genotypes 2</p></def></def-item><def-item><term>HEV-3</term><def><p id="Par7">Genotypes 3</p></def></def-item><def-item><term>HEV-4</term><def><p id="Par8">Genotypes 4</p></def></def-item><def-item><term>IFN-&#x003b1;</term><def><p id="Par9">Interferon-&#x003b1;</p></def></def-item><def-item><term>FHF</term><def><p id="Par10">Fulminant hepatitis failure</p></def></def-item><def-item><term>eHEV</term><def><p id="Par11">Enveloped HEV</p></def></def-item><def-item><term>UTR</term><def><p id="Par12">Untranslated region</p></def></def-item><def-item><term>ORFs</term><def><p id="Par13">Open reading frames</p></def></def-item><def-item><term>Met</term><def><p id="Par14">Methyltransferase</p></def></def-item><def-item><term>Y</term><def><p id="Par15">Y-domain</p></def></def-item><def-item><term>PCP</term><def><p id="Par16">Papain-like cysteine protease</p></def></def-item><def-item><term>HVR</term><def><p id="Par17">Hypervariable region</p></def></def-item><def-item><term>X</term><def><p id="Par18">Macrodomain</p></def></def-item><def-item><term>Hel</term><def><p id="Par19">RNA helicase</p></def></def-item><def-item><term>RdRp</term><def><p id="Par20">RNA-dependent RNA polymerase</p></def></def-item><def-item><term>DIC</term><def><p id="Par21">Disseminated intravascular coagulation</p></def></def-item><def-item><term>HBV</term><def><p id="Par22">Hepatitis B virus</p></def></def-item><def-item><term>HCV</term><def><p id="Par23">Hepatitis C virus</p></def></def-item><def-item><term>ALT</term><def><p id="Par24">Alanine aminotransferase</p></def></def-item><def-item><term>AST</term><def><p id="Par25">Aspartate aminotransferase</p></def></def-item><def-item><term>HIV</term><def><p id="Par26">Human immunodeficiency virus</p></def></def-item><def-item><term>NK</term><def><p id="Par27">Natural killer</p></def></def-item><def-item><term>DCs</term><def><p id="Par28">Dendritic cells</p></def></def-item><def-item><term>CMV</term><def><p id="Par29">Cytomegalovirus</p></def></def-item><def-item><term>SARS</term><def><p id="Par30">Severe acute respiratory syndrome</p></def></def-item><def-item><term>HSV</term><def><p id="Par31">Herpes simplex virus</p></def></def-item><def-item><term>AVH</term><def><p id="Par32">Acute viral hepatitis</p></def></def-item><def-item><term>HCG</term><def><p id="Par33">Human chorionic gonadotropin</p></def></def-item><def-item><term>PR</term><def><p id="Par34">Progesterone receptor</p></def></def-item><def-item><term>PROGINS</term><def><p id="Par35">Progesterone receptor (PR) gene mutations</p></def></def-item><def-item><term>PIBF</term><def><p id="Par36">Progesterone-induced blocking factor</p></def></def-item><def-item><term>IRF-3</term><def><p id="Par37">Interferon regulatory factor 3</p></def></def-item><def-item><term>MAVS</term><def><p id="Par38">Mitochondrial antiviral-signaling protein</p></def></def-item><def-item><term>TBK1</term><def><p id="Par39">TANK-binding kinase 1</p></def></def-item><def-item><term>FDA</term><def><p id="Par40">Food and Drug Administration</p></def></def-item><def-item><term>PPMO</term><def><p id="Par41">Peptide-conjugated morpholino oligomers</p></def></def-item><def-item><term>2CMG</term><def><p id="Par42">2&#x02032;-C-methylguanosine</p></def></def-item><def-item><term>VBDs</term><def><p id="Par43">Voluntary blood donors</p></def></def-item></def-list></glossary><fn-group><fn><p><bold>Publisher&#x02019;s Note</bold></p><p>Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p></fn></fn-group><ack><p>Not applicable.</p></ack><notes notes-type="author-contribution"><title>Authors&#x02019; contributions</title><p>Manuscript writing (CW, XW and JX). The author(s) read and approved the final manuscript.</p></notes><notes notes-type="funding-information"><title>Funding</title><p>Not applicable.</p></notes><notes notes-type="data-availability"><title>Availability of data and materials</title><p>Not applicable.</p></notes><notes id="FPar4"><title>Ethics approval and consent to participate</title><p id="Par67">Not applicable.</p></notes><notes id="FPar5"><title>Consent for publication</title><p id="Par68">Not applicable.</p></notes><notes id="FPar6" notes-type="COI-statement"><title>Competing interests</title><p id="Par69">The authors declare no competing interest.</p></notes><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nimgaonkar</surname><given-names>I</given-names></name><name><surname>Ding</surname><given-names>Q</given-names></name><name><surname>Schwartz</surname><given-names>RE</given-names></name><name><surname>Ploss</surname><given-names>A</given-names></name></person-group><article-title>Hepatitis E virus: advances and challenges</article-title><source>Nat Rev Gastroenterol Hepatol</source><year>2018</year><volume>15</volume><fpage>96</fpage><lpage>110</lpage><?supplied-pmid 29162935?><pub-id pub-id-type="pmid">29162935</pub-id></element-citation></ref><ref id="CR2"><label>2.</label><mixed-citation publication-type="other">World Health Organization. Hepatitis E. <ext-link ext-link-type="uri" xlink:href="https://www.who.int/en/news-room/fact-sheets/detail/hepatitis-e">https://www.who.int/en/news-room/fact-sheets/detail/hepatitis-e</ext-link>. Accessed 8 July 2019.</mixed-citation></ref><ref id="CR3"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bazerbachi</surname><given-names>F</given-names></name><name><surname>Haffar</surname><given-names>S</given-names></name><name><surname>Garg</surname><given-names>SK</given-names></name><name><surname>Lake</surname><given-names>JR</given-names></name></person-group><article-title>Extra-hepatic manifestations associated with hepatitis E virus infection: a comprehensive review of the literature</article-title><source>Gastroenterol Rep (Oxf)</source><year>2016</year><volume>4</volume><fpage>1</fpage><lpage>15</lpage><pub-id pub-id-type="pmid">26358655</pub-id></element-citation></ref><ref id="CR4"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Khuroo</surname><given-names>MS</given-names></name><name><surname>Khuroo</surname><given-names>MS</given-names></name><name><surname>Khuroo</surname><given-names>NS</given-names></name></person-group><article-title>Hepatitis E: discovery, global impact, control and cure</article-title><source>World J Gastroenterol</source><year>2016</year><volume>22</volume><fpage>7030</fpage><lpage>7045</lpage><?supplied-pmid 27610014?><pub-id pub-id-type="pmid">27610014</pub-id></element-citation></ref><ref id="CR5"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Meng</surname><given-names>XJ</given-names></name></person-group><article-title>Zoonotic and foodborne transmission of hepatitis E virus</article-title><source>Semin Liver Dis</source><year>2013</year><volume>33</volume><fpage>41</fpage><lpage>49</lpage><?supplied-pmid 23564388?><pub-id pub-id-type="pmid">23564388</pub-id></element-citation></ref><ref id="CR6"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rivadulla</surname><given-names>E</given-names></name><name><surname>Varela</surname><given-names>MF</given-names></name><name><surname>Mesquita</surname><given-names>JR</given-names></name><name><surname>Nascimento</surname><given-names>MSJ</given-names></name><name><surname>Romalde</surname><given-names>JL</given-names></name></person-group><article-title>Detection of hepatitis E virus in shellfish harvesting areas from Galicia (northwestern Spain)</article-title><source>Viruses</source><year>2019</year><volume>11</volume><issue>7</issue><fpage>618</fpage></element-citation></ref><ref id="CR7"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Geng</surname><given-names>Y</given-names></name><name><surname>Zhao</surname><given-names>C</given-names></name><name><surname>Geng</surname><given-names>K</given-names></name><name><surname>Wang</surname><given-names>C</given-names></name><name><surname>Wang</surname><given-names>X</given-names></name><name><surname>Liu</surname><given-names>H</given-names></name><name><surname>Wang</surname><given-names>Y</given-names></name></person-group><article-title>High seroprevalence of hepatitis E virus in rabbit slaughterhouse workers</article-title><source>Transbound Emerg Dis</source><year>2019</year><volume>66</volume><fpage>1085</fpage><lpage>1089</lpage><?supplied-pmid 30661292?><pub-id pub-id-type="pmid">30661292</pub-id></element-citation></ref><ref id="CR8"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Said</surname><given-names>B</given-names></name><name><surname>Ijaz</surname><given-names>S</given-names></name><name><surname>Kafatos</surname><given-names>G</given-names></name><name><surname>Booth</surname><given-names>L</given-names></name><name><surname>Thomas</surname><given-names>HL</given-names></name><name><surname>Walsh</surname><given-names>A</given-names></name><name><surname>Ramsay</surname><given-names>M</given-names></name><name><surname>Morgan</surname><given-names>D</given-names></name><name><surname>Hepatitis</surname><given-names>EIIT</given-names></name></person-group><article-title>Hepatitis E outbreak on cruise ship</article-title><source>Emerg Infect Dis</source><year>2009</year><volume>15</volume><fpage>1738</fpage><lpage>1744</lpage><?supplied-pmid 19891860?><pub-id pub-id-type="pmid">19891860</pub-id></element-citation></ref><ref id="CR9"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tei</surname><given-names>S</given-names></name><name><surname>Kitajima</surname><given-names>N</given-names></name><name><surname>Takahashi</surname><given-names>K</given-names></name><name><surname>Mishiro</surname><given-names>S</given-names></name></person-group><article-title>Zoonotic transmission of hepatitis E virus from deer to human beings</article-title><source>Lancet</source><year>2003</year><volume>362</volume><fpage>371</fpage><lpage>373</lpage><?supplied-pmid 12907011?><pub-id pub-id-type="pmid">12907011</pub-id></element-citation></ref><ref id="CR10"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Capai</surname><given-names>L</given-names></name><name><surname>Charrel</surname><given-names>R</given-names></name><name><surname>Falchi</surname><given-names>A</given-names></name></person-group><article-title>Hepatitis E in high-income countries: what do we know? And what are the knowledge gaps?</article-title><source>Viruses</source><year>2018</year><volume>10</volume><issue>6</issue><fpage>285</fpage></element-citation></ref><ref id="CR11"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Domanovic</surname><given-names>D</given-names></name><name><surname>Tedder</surname><given-names>R</given-names></name><name><surname>Blumel</surname><given-names>J</given-names></name><name><surname>Zaaijer</surname><given-names>H</given-names></name><name><surname>Gallian</surname><given-names>P</given-names></name><name><surname>Niederhauser</surname><given-names>C</given-names></name><name><surname>Sauleda Oliveras</surname><given-names>S</given-names></name><name><surname>O'Riordan</surname><given-names>J</given-names></name><name><surname>Boland</surname><given-names>F</given-names></name><name><surname>Harritshoj</surname><given-names>L</given-names></name><etal/></person-group><article-title>Hepatitis E and blood donation safety in selected European countries: a shift to screening?</article-title><source>Euro Surveill</source><year>2017</year><volume>22</volume><issue>16</issue><fpage>30514</fpage><?supplied-pmid 28449730?><pub-id pub-id-type="pmid">28449730</pub-id></element-citation></ref><ref id="CR12"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Himmelsbach</surname><given-names>K</given-names></name><name><surname>Bender</surname><given-names>D</given-names></name><name><surname>Hildt</surname><given-names>E</given-names></name></person-group><article-title>Life cycle and morphogenesis of the hepatitis E virus</article-title><source>Emerg Microbes Infect</source><year>2018</year><volume>7</volume><fpage>196</fpage><?supplied-pmid 30498191?><pub-id pub-id-type="pmid">30498191</pub-id></element-citation></ref><ref id="CR13"><label>13.</label><mixed-citation publication-type="other">Kamar N, Abravanel F, Behrendt P, Hofmann J, Pageaux GP, Barbet C, Moal V, Couzi L, Horvatits T, De Man RA, et al. Ribavirin for hepatitis E virus infection after organ transplantation: a large European retrospective multicenter study. Clin Infect Dis. 2019. 10.1093/cid/ciz953.</mixed-citation></ref><ref id="CR14"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kamar</surname><given-names>N</given-names></name><name><surname>Izopet</surname><given-names>J</given-names></name><name><surname>Tripon</surname><given-names>S</given-names></name><name><surname>Bismuth</surname><given-names>M</given-names></name><name><surname>Hillaire</surname><given-names>S</given-names></name><name><surname>Dumortier</surname><given-names>J</given-names></name><name><surname>Radenne</surname><given-names>S</given-names></name><name><surname>Coilly</surname><given-names>A</given-names></name><name><surname>Garrigue</surname><given-names>V</given-names></name><name><surname>D'Alteroche</surname><given-names>L</given-names></name><etal/></person-group><article-title>Ribavirin for chronic hepatitis E virus infection in transplant recipients</article-title><source>N Engl J Med</source><year>2014</year><volume>370</volume><fpage>1111</fpage><lpage>1120</lpage><?supplied-pmid 24645943?><pub-id pub-id-type="pmid">24645943</pub-id></element-citation></ref><ref id="CR15"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shao</surname><given-names>Z</given-names></name><name><surname>Al Tibi</surname><given-names>M</given-names></name><name><surname>Wakim-Fleming</surname><given-names>J</given-names></name></person-group><article-title>Update on viral hepatitis in pregnancy</article-title><source>Cleve Clin J Med</source><year>2017</year><volume>84</volume><fpage>202</fpage><lpage>206</lpage><?supplied-pmid 28322675?><pub-id pub-id-type="pmid">28322675</pub-id></element-citation></ref><ref id="CR16"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhu</surname><given-names>FC</given-names></name><name><surname>Zhang</surname><given-names>J</given-names></name><name><surname>Zhang</surname><given-names>XF</given-names></name><name><surname>Zhou</surname><given-names>C</given-names></name><name><surname>Wang</surname><given-names>ZZ</given-names></name><name><surname>Huang</surname><given-names>SJ</given-names></name><name><surname>Wang</surname><given-names>H</given-names></name><name><surname>Yang</surname><given-names>CL</given-names></name><name><surname>Jiang</surname><given-names>HM</given-names></name><name><surname>Cai</surname><given-names>JP</given-names></name><etal/></person-group><article-title>Efficacy and safety of a recombinant hepatitis E vaccine in healthy adults: a large-scale, randomised, double-blind placebo-controlled, phase 3 trial</article-title><source>Lancet</source><year>2010</year><volume>376</volume><fpage>895</fpage><lpage>902</lpage><?supplied-pmid 20728932?><pub-id pub-id-type="pmid">20728932</pub-id></element-citation></ref><ref id="CR17"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kenney</surname><given-names>SP</given-names></name><name><surname>Meng</surname><given-names>XJ</given-names></name></person-group><article-title>Therapeutic targets for the treatment of hepatitis E virus infection</article-title><source>Expert Opin Ther Targets</source><year>2015</year><volume>19</volume><fpage>1245</fpage><lpage>1260</lpage><?supplied-pmid 26073772?><pub-id pub-id-type="pmid">26073772</pub-id></element-citation></ref><ref id="CR18"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Khuroo</surname><given-names>MS</given-names></name><name><surname>Kamili</surname><given-names>S</given-names></name></person-group><article-title>Aetiology, clinical course and outcome of sporadic acute viral hepatitis in pregnancy</article-title><source>J Viral Hepat</source><year>2003</year><volume>10</volume><fpage>61</fpage><lpage>69</lpage><?supplied-pmid 12558914?><pub-id pub-id-type="pmid">12558914</pub-id></element-citation></ref><ref id="CR19"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Perez-Gracia</surname><given-names>MT</given-names></name><name><surname>Suay-Garcia</surname><given-names>B</given-names></name><name><surname>Mateos-Lindemann</surname><given-names>ML</given-names></name></person-group><article-title>Hepatitis E and pregnancy: current state</article-title><source>Rev Med Virol</source><year>2017</year><volume>27</volume><issue>3</issue><fpage>e1929</fpage><?supplied-pmid 28318080?><pub-id pub-id-type="pmid">28318080</pub-id></element-citation></ref><ref id="CR20"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Patra</surname><given-names>S</given-names></name><name><surname>Kumar</surname><given-names>A</given-names></name><name><surname>Trivedi</surname><given-names>SS</given-names></name><name><surname>Puri</surname><given-names>M</given-names></name><name><surname>Sarin</surname><given-names>SK</given-names></name></person-group><article-title>Maternal and fetal outcomes in pregnant women with acute hepatitis E virus infection</article-title><source>Ann Intern Med</source><year>2007</year><volume>147</volume><fpage>28</fpage><lpage>33</lpage><?supplied-pmid 17606958?><pub-id pub-id-type="pmid">17606958</pub-id></element-citation></ref><ref id="CR21"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Khuroo</surname><given-names>MS</given-names></name><name><surname>Khuroo</surname><given-names>MS</given-names></name><name><surname>Khuroo</surname><given-names>NS</given-names></name></person-group><article-title>Transmission of hepatitis E virus in developing countries</article-title><source>Viruses</source><year>2016</year><volume>8</volume><issue>9</issue><fpage>253</fpage></element-citation></ref><ref id="CR22"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Khuroo</surname><given-names>MS</given-names></name><name><surname>Kamili</surname><given-names>S</given-names></name><name><surname>Khuroo</surname><given-names>MS</given-names></name></person-group><article-title>Clinical course and duration of viremia in vertically transmitted hepatitis E virus (HEV) infection in babies born to HEV-infected mothers</article-title><source>J Viral Hepat</source><year>2009</year><volume>16</volume><fpage>519</fpage><lpage>523</lpage><?supplied-pmid 19228284?><pub-id pub-id-type="pmid">19228284</pub-id></element-citation></ref><ref id="CR23"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Debing</surname><given-names>Y</given-names></name><name><surname>Neyts</surname><given-names>J</given-names></name></person-group><article-title>Antiviral strategies for hepatitis E virus</article-title><source>Antivir Res</source><year>2014</year><volume>102</volume><fpage>106</fpage><lpage>118</lpage><?supplied-pmid 24374149?><pub-id pub-id-type="pmid">24374149</pub-id></element-citation></ref><ref id="CR24"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kinast</surname><given-names>V</given-names></name><name><surname>Burkard</surname><given-names>TL</given-names></name><name><surname>Todt</surname><given-names>D</given-names></name><name><surname>Steinmann</surname><given-names>E</given-names></name></person-group><article-title>Hepatitis E virus drug development</article-title><source>Viruses</source><year>2019</year><volume>11</volume><issue>6</issue><fpage>485</fpage></element-citation></ref><ref id="CR25"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sinclair</surname><given-names>SM</given-names></name><name><surname>Jones</surname><given-names>JK</given-names></name><name><surname>Miller</surname><given-names>RK</given-names></name><name><surname>Greene</surname><given-names>MF</given-names></name><name><surname>Kwo</surname><given-names>PY</given-names></name><name><surname>Maddrey</surname><given-names>WC</given-names></name></person-group><article-title>The ribavirin pregnancy registry: an interim analysis of potential teratogenicity at the mid-point of enrollment</article-title><source>Drug Saf</source><year>2017</year><volume>40</volume><fpage>1205</fpage><lpage>1218</lpage><?supplied-pmid 28689333?><pub-id pub-id-type="pmid">28689333</pub-id></element-citation></ref><ref id="CR26"><label>26.</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Emerson</surname><given-names>SU</given-names></name><name><surname>Purcell</surname><given-names>RH</given-names></name></person-group><source>Hepatitis E Virus</source><year>2013</year><publisher-loc>Philadelphia</publisher-loc><publisher-name>Lippincott Williams &#x00026; Wilkins</publisher-name></element-citation></ref><ref id="CR27"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Karpe</surname><given-names>YA</given-names></name><name><surname>Lole</surname><given-names>KS</given-names></name></person-group><article-title>Deubiquitination activity associated with hepatitis E virus putative papain-like cysteine protease</article-title><source>J Gen Virol</source><year>2011</year><volume>92</volume><fpage>2088</fpage><lpage>2092</lpage><?supplied-pmid 21653754?><pub-id pub-id-type="pmid">21653754</pub-id></element-citation></ref><ref id="CR28"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lhomme</surname><given-names>S</given-names></name><name><surname>Abravanel</surname><given-names>F</given-names></name><name><surname>Dubois</surname><given-names>M</given-names></name><name><surname>Sandres-Saune</surname><given-names>K</given-names></name><name><surname>Mansuy</surname><given-names>JM</given-names></name><name><surname>Rostaing</surname><given-names>L</given-names></name><name><surname>Kamar</surname><given-names>N</given-names></name><name><surname>Izopet</surname><given-names>J</given-names></name></person-group><article-title>Characterization of the polyproline region of the hepatitis E virus in immunocompromised patients</article-title><source>J Virol</source><year>2014</year><volume>88</volume><fpage>12017</fpage><lpage>12025</lpage><?supplied-pmid 25100839?><pub-id pub-id-type="pmid">25100839</pub-id></element-citation></ref><ref id="CR29"><label>29.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Karpe</surname><given-names>YA</given-names></name><name><surname>Lole</surname><given-names>KS</given-names></name></person-group><article-title>RNA 5&#x02032;-triphosphatase activity of the hepatitis E virus helicase domain</article-title><source>J Virol</source><year>2010</year><volume>84</volume><fpage>9637</fpage><lpage>9641</lpage><?supplied-pmid 20592074?><pub-id pub-id-type="pmid">20592074</pub-id></element-citation></ref><ref id="CR30"><label>30.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Karpe</surname><given-names>YA</given-names></name><name><surname>Lole</surname><given-names>KS</given-names></name></person-group><article-title>NTPase and 5&#x02032; to 3&#x02032; RNA duplex-unwinding activities of the hepatitis E virus helicase domain</article-title><source>J Virol</source><year>2010</year><volume>84</volume><fpage>3595</fpage><lpage>3602</lpage><?supplied-pmid 20071563?><pub-id pub-id-type="pmid">20071563</pub-id></element-citation></ref><ref id="CR31"><label>31.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Agrawal</surname><given-names>S</given-names></name><name><surname>Gupta</surname><given-names>D</given-names></name><name><surname>Panda</surname><given-names>SK</given-names></name></person-group><article-title>The 3&#x02032; end of hepatitis E virus (HEV) genome binds specifically to the viral RNA-dependent RNA polymerase (RdRp)</article-title><source>Virology</source><year>2001</year><volume>282</volume><fpage>87</fpage><lpage>101</lpage><?supplied-pmid 11259193?><pub-id pub-id-type="pmid">11259193</pub-id></element-citation></ref><ref id="CR32"><label>32.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rehman</surname><given-names>S</given-names></name><name><surname>Kapur</surname><given-names>N</given-names></name><name><surname>Durgapal</surname><given-names>H</given-names></name><name><surname>Panda</surname><given-names>SK</given-names></name></person-group><article-title>Subcellular localization of hepatitis E virus (HEV) replicase</article-title><source>Virology</source><year>2008</year><volume>370</volume><fpage>77</fpage><lpage>92</lpage><?supplied-pmid 17904184?><pub-id pub-id-type="pmid">17904184</pub-id></element-citation></ref><ref id="CR33"><label>33.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Koonin</surname><given-names>EV</given-names></name><name><surname>Gorbalenya</surname><given-names>AE</given-names></name><name><surname>Purdy</surname><given-names>MA</given-names></name><name><surname>Rozanov</surname><given-names>MN</given-names></name><name><surname>Reyes</surname><given-names>GR</given-names></name><name><surname>Bradley</surname><given-names>DW</given-names></name></person-group><article-title>Computer-assisted assignment of functional domains in the nonstructural polyprotein of hepatitis E virus: delineation of an additional group of positive-strand RNA plant and animal viruses</article-title><source>Proc Natl Acad Sci U S A</source><year>1992</year><volume>89</volume><fpage>8259</fpage><lpage>8263</lpage><?supplied-pmid 1518855?><pub-id pub-id-type="pmid">1518855</pub-id></element-citation></ref><ref id="CR34"><label>34.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Graff</surname><given-names>J</given-names></name><name><surname>Torian</surname><given-names>U</given-names></name><name><surname>Nguyen</surname><given-names>H</given-names></name><name><surname>Emerson</surname><given-names>SU</given-names></name></person-group><article-title>A bicistronic subgenomic mRNA encodes both the ORF2 and ORF3 proteins of hepatitis E virus</article-title><source>J Virol</source><year>2006</year><volume>80</volume><fpage>5919</fpage><lpage>5926</lpage><?supplied-pmid 16731930?><pub-id pub-id-type="pmid">16731930</pub-id></element-citation></ref><ref id="CR35"><label>35.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yin</surname><given-names>X</given-names></name><name><surname>Ying</surname><given-names>D</given-names></name><name><surname>Lhomme</surname><given-names>S</given-names></name><name><surname>Tang</surname><given-names>Z</given-names></name><name><surname>Walker</surname><given-names>CM</given-names></name><name><surname>Xia</surname><given-names>N</given-names></name><name><surname>Zheng</surname><given-names>Z</given-names></name><name><surname>Feng</surname><given-names>Z</given-names></name></person-group><article-title>Origin, antigenicity, and function of a secreted form of ORF2 in hepatitis E virus infection</article-title><source>Proc Natl Acad Sci U S A</source><year>2018</year><volume>115</volume><fpage>4773</fpage><lpage>4778</lpage><?supplied-pmid 29669922?><pub-id pub-id-type="pmid">29669922</pub-id></element-citation></ref><ref id="CR36"><label>36.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Montpellier</surname><given-names>C</given-names></name><name><surname>Wychowski</surname><given-names>C</given-names></name><name><surname>Sayed</surname><given-names>IM</given-names></name><name><surname>Meunier</surname><given-names>JC</given-names></name><name><surname>Saliou</surname><given-names>JM</given-names></name><name><surname>Ankavay</surname><given-names>M</given-names></name><name><surname>Bull</surname><given-names>A</given-names></name><name><surname>Pillez</surname><given-names>A</given-names></name><name><surname>Abravanel</surname><given-names>F</given-names></name><name><surname>Helle</surname><given-names>F</given-names></name><etal/></person-group><article-title>Hepatitis E virus lifecycle and identification of 3 forms of the ORF2 capsid protein</article-title><source>Gastroenterology</source><year>2018</year><volume>154</volume><fpage>211</fpage><lpage>223.e218</lpage><?supplied-pmid 28958858?><pub-id pub-id-type="pmid">28958858</pub-id></element-citation></ref><ref id="CR37"><label>37.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cao</surname><given-names>D</given-names></name><name><surname>Meng</surname><given-names>XJ</given-names></name></person-group><article-title>Molecular biology and replication of hepatitis E virus</article-title><source>Emerg Microbes Infect</source><year>2012</year><volume>1</volume><fpage>e17</fpage><?supplied-pmid 26038426?><pub-id pub-id-type="pmid">26038426</pub-id></element-citation></ref><ref id="CR38"><label>38.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yin</surname><given-names>X</given-names></name><name><surname>Ambardekar</surname><given-names>C</given-names></name><name><surname>Lu</surname><given-names>Y</given-names></name><name><surname>Feng</surname><given-names>Z</given-names></name></person-group><article-title>Distinct entry mechanisms for nonenveloped and quasi-enveloped hepatitis E viruses</article-title><source>J Virol</source><year>2016</year><volume>90</volume><fpage>4232</fpage><lpage>4242</lpage><?supplied-pmid 26865708?><pub-id pub-id-type="pmid">26865708</pub-id></element-citation></ref><ref id="CR39"><label>39.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Perttila</surname><given-names>J</given-names></name><name><surname>Spuul</surname><given-names>P</given-names></name><name><surname>Ahola</surname><given-names>T</given-names></name></person-group><article-title>Early secretory pathway localization and lack of processing for hepatitis E virus replication protein pORF1</article-title><source>J Gen Virol</source><year>2013</year><volume>94</volume><fpage>807</fpage><lpage>816</lpage><?supplied-pmid 23255617?><pub-id pub-id-type="pmid">23255617</pub-id></element-citation></ref><ref id="CR40"><label>40.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Graff</surname><given-names>J</given-names></name><name><surname>Nguyen</surname><given-names>H</given-names></name><name><surname>Kasorndorkbua</surname><given-names>C</given-names></name><name><surname>Halbur</surname><given-names>PG</given-names></name><name><surname>St Claire</surname><given-names>M</given-names></name><name><surname>Purcell</surname><given-names>RH</given-names></name><name><surname>Emerson</surname><given-names>SU</given-names></name></person-group><article-title>In vitro and in vivo mutational analysis of the 3&#x02032;-terminal regions of hepatitis e virus genomes and replicons</article-title><source>J Virol</source><year>2005</year><volume>79</volume><fpage>1017</fpage><lpage>1026</lpage><?supplied-pmid 15613330?><pub-id pub-id-type="pmid">15613330</pub-id></element-citation></ref><ref id="CR41"><label>41.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Surjit</surname><given-names>M</given-names></name><name><surname>Jameel</surname><given-names>S</given-names></name><name><surname>Lal</surname><given-names>SK</given-names></name></person-group><article-title>The ORF2 protein of hepatitis E virus binds the 5&#x02032; region of viral RNA</article-title><source>J Virol</source><year>2004</year><volume>78</volume><fpage>320</fpage><lpage>328</lpage><?supplied-pmid 14671114?><pub-id pub-id-type="pmid">14671114</pub-id></element-citation></ref><ref id="CR42"><label>42.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kar</surname><given-names>P</given-names></name><name><surname>Sengupta</surname><given-names>A</given-names></name></person-group><article-title>A guide to the management of hepatitis E infection during pregnancy</article-title><source>Expert Rev Gastroenterol Hepatol</source><year>2019</year><volume>13</volume><fpage>205</fpage><lpage>211</lpage><?supplied-pmid 30791760?><pub-id pub-id-type="pmid">30791760</pub-id></element-citation></ref><ref id="CR43"><label>43.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Khuroo</surname><given-names>MS</given-names></name><name><surname>Teli</surname><given-names>MR</given-names></name><name><surname>Skidmore</surname><given-names>S</given-names></name><name><surname>Sofi</surname><given-names>MA</given-names></name><name><surname>Khuroo</surname><given-names>MI</given-names></name></person-group><article-title>Incidence and severity of viral hepatitis in pregnancy</article-title><source>Am J Med</source><year>1981</year><volume>70</volume><fpage>252</fpage><lpage>255</lpage><?supplied-pmid 6781338?><pub-id pub-id-type="pmid">6781338</pub-id></element-citation></ref><ref id="CR44"><label>44.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jaiswal</surname><given-names>SP</given-names></name><name><surname>Jain</surname><given-names>AK</given-names></name><name><surname>Naik</surname><given-names>G</given-names></name><name><surname>Soni</surname><given-names>N</given-names></name><name><surname>Chitnis</surname><given-names>DS</given-names></name></person-group><article-title>Viral hepatitis during pregnancy</article-title><source>Int J Gynaecol Obstet</source><year>2001</year><volume>72</volume><fpage>103</fpage><lpage>108</lpage><?supplied-pmid 11166742?><pub-id pub-id-type="pmid">11166742</pub-id></element-citation></ref><ref id="CR45"><label>45.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Aziz</surname><given-names>AB</given-names></name><name><surname>Hamid</surname><given-names>S</given-names></name><name><surname>Iqbal</surname><given-names>S</given-names></name><name><surname>Islam</surname><given-names>W</given-names></name><name><surname>Karim</surname><given-names>SA</given-names></name></person-group><article-title>Prevalence and severity of viral hepatitis in Pakistani pregnant women: a five year hospital based study</article-title><source>J Pak Med Assoc</source><year>1997</year><volume>47</volume><fpage>198</fpage><lpage>201</lpage><?supplied-pmid 9339616?><pub-id pub-id-type="pmid">9339616</pub-id></element-citation></ref><ref id="CR46"><label>46.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dahiya</surname><given-names>M</given-names></name><name><surname>Kumar</surname><given-names>A</given-names></name><name><surname>Kar</surname><given-names>P</given-names></name><name><surname>Gupta</surname><given-names>RK</given-names></name><name><surname>Kumar</surname><given-names>A</given-names></name></person-group><article-title>Acute viral hepatitis in third trimester of pregnancy</article-title><source>Indian J Gastroenterol</source><year>2005</year><volume>24</volume><fpage>128</fpage><lpage>129</lpage><?supplied-pmid 16041115?><pub-id pub-id-type="pmid">16041115</pub-id></element-citation></ref><ref id="CR47"><label>47.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shrestha</surname><given-names>P</given-names></name><name><surname>Bhandari</surname><given-names>D</given-names></name><name><surname>Sharma</surname><given-names>D</given-names></name><name><surname>Bhandari</surname><given-names>BP</given-names></name></person-group><article-title>A study of viral hepatitis during pregnancy in Nepal medical college teaching hospital</article-title><source>Nepal Med Coll J</source><year>2009</year><volume>11</volume><fpage>192</fpage><lpage>194</lpage><?supplied-pmid 20334069?><pub-id pub-id-type="pmid">20334069</pub-id></element-citation></ref><ref id="CR48"><label>48.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Khuroo</surname><given-names>MS</given-names></name><name><surname>Kamili</surname><given-names>S</given-names></name><name><surname>Jameel</surname><given-names>S</given-names></name></person-group><article-title>Vertical transmission of hepatitis E virus</article-title><source>Lancet</source><year>1995</year><volume>345</volume><fpage>1025</fpage><lpage>1026</lpage><?supplied-pmid 7723501?><pub-id pub-id-type="pmid">7723501</pub-id></element-citation></ref><ref id="CR49"><label>49.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lachish</surname><given-names>T</given-names></name><name><surname>Erez</surname><given-names>O</given-names></name><name><surname>Daudi</surname><given-names>N</given-names></name><name><surname>Shouval</surname><given-names>D</given-names></name><name><surname>Schwartz</surname><given-names>E</given-names></name></person-group><article-title>Acute hepatitis E virus in pregnant women in Israel and in other industrialized countries</article-title><source>J Clin Virol</source><year>2015</year><volume>73</volume><fpage>20</fpage><lpage>24</lpage><?supplied-pmid 26521225?><pub-id pub-id-type="pmid">26521225</pub-id></element-citation></ref><ref id="CR50"><label>50.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Anty</surname><given-names>R</given-names></name><name><surname>Ollier</surname><given-names>L</given-names></name><name><surname>Peron</surname><given-names>JM</given-names></name><name><surname>Nicand</surname><given-names>E</given-names></name><name><surname>Cannavo</surname><given-names>I</given-names></name><name><surname>Bongain</surname><given-names>A</given-names></name><name><surname>Giordanengo</surname><given-names>V</given-names></name><name><surname>Tran</surname><given-names>A</given-names></name></person-group><article-title>First case report of an acute genotype 3 hepatitis E infected pregnant woman living in south-eastern France</article-title><source>J Clin Virol</source><year>2012</year><volume>54</volume><fpage>76</fpage><lpage>78</lpage><?supplied-pmid 22336086?><pub-id pub-id-type="pmid">22336086</pub-id></element-citation></ref><ref id="CR51"><label>51.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tabatabai</surname><given-names>J</given-names></name><name><surname>Wenzel</surname><given-names>JJ</given-names></name><name><surname>Soboletzki</surname><given-names>M</given-names></name><name><surname>Flux</surname><given-names>C</given-names></name><name><surname>Navid</surname><given-names>MH</given-names></name><name><surname>Schnitzler</surname><given-names>P</given-names></name></person-group><article-title>First case report of an acute hepatitis E subgenotype 3c infection during pregnancy in Germany</article-title><source>J Clin Virol</source><year>2014</year><volume>61</volume><fpage>170</fpage><lpage>172</lpage><?supplied-pmid 24996764?><pub-id pub-id-type="pmid">24996764</pub-id></element-citation></ref><ref id="CR52"><label>52.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>RC</given-names></name><name><surname>Ge</surname><given-names>SX</given-names></name><name><surname>Li</surname><given-names>YP</given-names></name><name><surname>Zheng</surname><given-names>YJ</given-names></name><name><surname>Nong</surname><given-names>Y</given-names></name><name><surname>Guo</surname><given-names>QS</given-names></name><name><surname>Zhang</surname><given-names>J</given-names></name><name><surname>Ng</surname><given-names>MH</given-names></name><name><surname>Xia</surname><given-names>NS</given-names></name></person-group><article-title>Seroprevalence of hepatitis E virus infection, rural southern People's Republic of China</article-title><source>Emerg Infect Dis</source><year>2006</year><volume>12</volume><fpage>1682</fpage><lpage>1688</lpage><?supplied-pmid 17283617?><pub-id pub-id-type="pmid">17283617</pub-id></element-citation></ref><ref id="CR53"><label>53.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tang</surname><given-names>WF</given-names></name><name><surname>Kong</surname><given-names>DG</given-names></name><name><surname>Wang</surname><given-names>YH</given-names></name><name><surname>Liu</surname><given-names>MQ</given-names></name><name><surname>Hu</surname><given-names>Q</given-names></name></person-group><article-title>Hepatitis E virus infection in Wuhan, Central China</article-title><source>Arch Virol</source><year>2019</year><volume>164</volume><fpage>27</fpage><lpage>32</lpage><?supplied-pmid 30229302?><pub-id pub-id-type="pmid">30229302</pub-id></element-citation></ref><ref id="CR54"><label>54.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cong</surname><given-names>W</given-names></name><name><surname>Sui</surname><given-names>JC</given-names></name><name><surname>Zhang</surname><given-names>XY</given-names></name><name><surname>Qian</surname><given-names>AD</given-names></name><name><surname>Chen</surname><given-names>J</given-names></name><name><surname>Zhu</surname><given-names>XQ</given-names></name></person-group><article-title>Seroprevalence of hepatitis E virus among pregnant women and control subjects in China</article-title><source>J Med Virol</source><year>2015</year><volume>87</volume><fpage>446</fpage><lpage>450</lpage><?supplied-pmid 25164987?><pub-id pub-id-type="pmid">25164987</pub-id></element-citation></ref><ref id="CR55"><label>55.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gu</surname><given-names>G</given-names></name><name><surname>Huang</surname><given-names>H</given-names></name><name><surname>Zhang</surname><given-names>L</given-names></name><name><surname>Bi</surname><given-names>Y</given-names></name><name><surname>Hu</surname><given-names>Y</given-names></name><name><surname>Zhou</surname><given-names>YH</given-names></name></person-group><article-title>Hepatitis E virus seroprevalence in pregnant women in Jiangsu, China, and postpartum evolution during six years</article-title><source>BMC Infect Dis</source><year>2015</year><volume>15</volume><fpage>560</fpage><?supplied-pmid 26653888?><pub-id pub-id-type="pmid">26653888</pub-id></element-citation></ref><ref id="CR56"><label>56.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Huang</surname><given-names>F</given-names></name><name><surname>Ma</surname><given-names>T</given-names></name><name><surname>Li</surname><given-names>L</given-names></name><name><surname>Zeng</surname><given-names>W</given-names></name><name><surname>Jing</surname><given-names>S</given-names></name></person-group><article-title>Low seroprevalence of hepatitis E virus infection in pregnant women in Yunnan, China</article-title><source>Braz J Infect Dis</source><year>2013</year><volume>17</volume><fpage>716</fpage><lpage>717</lpage><?supplied-pmid 24055390?><pub-id pub-id-type="pmid">24055390</pub-id></element-citation></ref><ref id="CR57"><label>57.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Drobeniuc</surname><given-names>J</given-names></name><name><surname>Meng</surname><given-names>J</given-names></name><name><surname>Reuter</surname><given-names>G</given-names></name><name><surname>Greene-Montfort</surname><given-names>T</given-names></name><name><surname>Khudyakova</surname><given-names>N</given-names></name><name><surname>Dimitrova</surname><given-names>Z</given-names></name><name><surname>Kamili</surname><given-names>S</given-names></name><name><surname>Teo</surname><given-names>CG</given-names></name></person-group><article-title>Serologic assays specific to immunoglobulin M antibodies against hepatitis E virus: pangenotypic evaluation of performances</article-title><source>Clin Infect Dis</source><year>2010</year><volume>51</volume><fpage>e24</fpage><lpage>e27</lpage><?supplied-pmid 20578874?><pub-id pub-id-type="pmid">20578874</pub-id></element-citation></ref><ref id="CR58"><label>58.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Khudyakov</surname><given-names>Y</given-names></name><name><surname>Kamili</surname><given-names>S</given-names></name></person-group><article-title>Serological diagnostics of hepatitis E virus infection</article-title><source>Virus Res</source><year>2011</year><volume>161</volume><fpage>84</fpage><lpage>92</lpage><?supplied-pmid 21704091?><pub-id pub-id-type="pmid">21704091</pub-id></element-citation></ref><ref id="CR59"><label>59.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Arends</surname><given-names>JE</given-names></name><name><surname>Ghisetti</surname><given-names>V</given-names></name><name><surname>Irving</surname><given-names>W</given-names></name><name><surname>Dalton</surname><given-names>HR</given-names></name><name><surname>Izopet</surname><given-names>J</given-names></name><name><surname>Hoepelman</surname><given-names>AI</given-names></name><name><surname>Salmon</surname><given-names>D</given-names></name></person-group><article-title>Hepatitis E: an emerging infection in high income countries</article-title><source>J Clin Virol</source><year>2014</year><volume>59</volume><fpage>81</fpage><lpage>88</lpage><?supplied-pmid 24388207?><pub-id pub-id-type="pmid">24388207</pub-id></element-citation></ref><ref id="CR60"><label>60.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Al-Sadeq</surname><given-names>DW</given-names></name><name><surname>Majdalawieh</surname><given-names>AF</given-names></name><name><surname>Mesleh</surname><given-names>AG</given-names></name><name><surname>Abdalla</surname><given-names>OM</given-names></name><name><surname>Nasrallah</surname><given-names>GK</given-names></name></person-group><article-title>Laboratory challenges in the diagnosis of hepatitis E virus</article-title><source>J Med Microbiol</source><year>2018</year><volume>67</volume><fpage>466</fpage><lpage>480</lpage><?supplied-pmid 29485390?><pub-id pub-id-type="pmid">29485390</pub-id></element-citation></ref><ref id="CR61"><label>61.</label><mixed-citation publication-type="other">Li M, Bu Q, Gong W, Li H, Wang L, Li S, Sridhar S, Cy Woo P, Wang L. Hepatitis E virus infection and its associated adverse feto-maternal outcomes among pregnant women in Qinhuangdao, China. J Matern Fetal Neonatal Med. 2019:1&#x02013;5. 10.1080/14767058.2019.1582630.</mixed-citation></ref><ref id="CR62"><label>62.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bouquet</surname><given-names>J</given-names></name><name><surname>Cheval</surname><given-names>J</given-names></name><name><surname>Rogee</surname><given-names>S</given-names></name><name><surname>Pavio</surname><given-names>N</given-names></name><name><surname>Eloit</surname><given-names>M</given-names></name></person-group><article-title>Identical consensus sequence and conserved genomic polymorphism of hepatitis E virus during controlled interspecies transmission</article-title><source>J Virol</source><year>2012</year><volume>86</volume><fpage>6238</fpage><lpage>6245</lpage><?supplied-pmid 22457521?><pub-id pub-id-type="pmid">22457521</pub-id></element-citation></ref><ref id="CR63"><label>63.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Aye</surname><given-names>TT</given-names></name><name><surname>Uchida</surname><given-names>T</given-names></name><name><surname>Ma</surname><given-names>XZ</given-names></name><name><surname>Iida</surname><given-names>F</given-names></name><name><surname>Shikata</surname><given-names>T</given-names></name><name><surname>Zhuang</surname><given-names>H</given-names></name><name><surname>Win</surname><given-names>KM</given-names></name></person-group><article-title>Complete nucleotide sequence of a hepatitis E virus isolated from the Xinjiang epidemic (1986-1988) of China</article-title><source>Nucleic Acids Res</source><year>1992</year><volume>20</volume><fpage>3512</fpage><?supplied-pmid 1630924?><pub-id pub-id-type="pmid">1630924</pub-id></element-citation></ref><ref id="CR64"><label>64.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Aslam</surname><given-names>A</given-names></name><name><surname>Susheela</surname><given-names>A</given-names></name><name><surname>Iriana</surname><given-names>S</given-names></name><name><surname>Chan</surname><given-names>SS</given-names></name><name><surname>Lau</surname><given-names>D</given-names></name></person-group><article-title>Acute hepatitis E superinfection leading to chronic hepatitis B reactivation</article-title><source>BMJ Case Rep</source><year>2018</year><volume>2018</volume><fpage>bcr2017223616</fpage></element-citation></ref><ref id="CR65"><label>65.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Blasco-Perrin</surname><given-names>H</given-names></name><name><surname>Madden</surname><given-names>RG</given-names></name><name><surname>Stanley</surname><given-names>A</given-names></name><name><surname>Crossan</surname><given-names>C</given-names></name><name><surname>Hunter</surname><given-names>JG</given-names></name><name><surname>Vine</surname><given-names>L</given-names></name><name><surname>Lane</surname><given-names>K</given-names></name><name><surname>Devooght-Johnson</surname><given-names>N</given-names></name><name><surname>McLaughlin</surname><given-names>C</given-names></name><name><surname>Petrik</surname><given-names>J</given-names></name><etal/></person-group><article-title>Hepatitis E virus in patients with decompensated chronic liver disease: a prospective UK/French study</article-title><source>Aliment Pharmacol Ther</source><year>2015</year><volume>42</volume><fpage>574</fpage><lpage>581</lpage><?supplied-pmid 26174470?><pub-id pub-id-type="pmid">26174470</pub-id></element-citation></ref><ref id="CR66"><label>66.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gad</surname><given-names>YZ</given-names></name><name><surname>Mousa</surname><given-names>N</given-names></name><name><surname>Shams</surname><given-names>M</given-names></name><name><surname>Elewa</surname><given-names>A</given-names></name></person-group><article-title>Seroprevalence of subclinical HEV infection in asymptomatic, apparently healthy, pregnant women in Dakahlya Governorate, Egypt</article-title><source>Asian J Transfus Sci</source><year>2011</year><volume>5</volume><fpage>136</fpage><lpage>139</lpage><?supplied-pmid 21897591?><pub-id pub-id-type="pmid">21897591</pub-id></element-citation></ref><ref id="CR67"><label>67.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sayed</surname><given-names>IM</given-names></name><name><surname>Vercouter</surname><given-names>AS</given-names></name><name><surname>Abdelwahab</surname><given-names>SF</given-names></name><name><surname>Vercauteren</surname><given-names>K</given-names></name><name><surname>Meuleman</surname><given-names>P</given-names></name></person-group><article-title>Is hepatitis E virus an emerging problem in industrialized countries?</article-title><source>Hepatology</source><year>2015</year><volume>62</volume><fpage>1883</fpage><lpage>1892</lpage><?supplied-pmid 26175182?><pub-id pub-id-type="pmid">26175182</pub-id></element-citation></ref><ref id="CR68"><label>68.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chau</surname><given-names>TN</given-names></name><name><surname>Lai</surname><given-names>ST</given-names></name><name><surname>Tse</surname><given-names>C</given-names></name><name><surname>Ng</surname><given-names>TK</given-names></name><name><surname>Leung</surname><given-names>VK</given-names></name><name><surname>Lim</surname><given-names>W</given-names></name><name><surname>Ng</surname><given-names>MH</given-names></name></person-group><article-title>Epidemiology and clinical features of sporadic hepatitis E as compared with hepatitis A</article-title><source>Am J Gastroenterol</source><year>2006</year><volume>101</volume><fpage>292</fpage><lpage>296</lpage><?supplied-pmid 16454833?><pub-id pub-id-type="pmid">16454833</pub-id></element-citation></ref><ref id="CR69"><label>69.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mansuy</surname><given-names>JM</given-names></name><name><surname>Abravanel</surname><given-names>F</given-names></name><name><surname>Miedouge</surname><given-names>M</given-names></name><name><surname>Mengelle</surname><given-names>C</given-names></name><name><surname>Merviel</surname><given-names>C</given-names></name><name><surname>Dubois</surname><given-names>M</given-names></name><name><surname>Kamar</surname><given-names>N</given-names></name><name><surname>Rostaing</surname><given-names>L</given-names></name><name><surname>Alric</surname><given-names>L</given-names></name><name><surname>Moreau</surname><given-names>J</given-names></name><etal/></person-group><article-title>Acute hepatitis E in south-west France over a 5-year period</article-title><source>J Clin Virol</source><year>2009</year><volume>44</volume><fpage>74</fpage><lpage>77</lpage><?supplied-pmid 18993112?><pub-id pub-id-type="pmid">18993112</pub-id></element-citation></ref><ref id="CR70"><label>70.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wedemeyer</surname><given-names>H</given-names></name><name><surname>Pischke</surname><given-names>S</given-names></name><name><surname>Manns</surname><given-names>MP</given-names></name></person-group><article-title>Pathogenesis and treatment of hepatitis e virus infection</article-title><source>Gastroenterology</source><year>2012</year><volume>142</volume><fpage>1388</fpage><lpage>1397.e1381</lpage><?supplied-pmid 22537448?><pub-id pub-id-type="pmid">22537448</pub-id></element-citation></ref><ref id="CR71"><label>71.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Donnelly</surname><given-names>MC</given-names></name><name><surname>Scobie</surname><given-names>L</given-names></name><name><surname>Crossan</surname><given-names>CL</given-names></name><name><surname>Dalton</surname><given-names>H</given-names></name><name><surname>Hayes</surname><given-names>PC</given-names></name><name><surname>Simpson</surname><given-names>KJ</given-names></name></person-group><article-title>Review article: hepatitis E-a concise review of virology, epidemiology, clinical presentation and therapy</article-title><source>Aliment Pharmacol Ther</source><year>2017</year><volume>46</volume><fpage>126</fpage><lpage>141</lpage><?supplied-pmid 28449246?><pub-id pub-id-type="pmid">28449246</pub-id></element-citation></ref><ref id="CR72"><label>72.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rayis</surname><given-names>DA</given-names></name><name><surname>Jumaa</surname><given-names>AM</given-names></name><name><surname>Gasim</surname><given-names>GI</given-names></name><name><surname>Karsany</surname><given-names>MS</given-names></name><name><surname>Adam</surname><given-names>I</given-names></name></person-group><article-title>An outbreak of hepatitis E and high maternal mortality at Port Sudan, eastern Sudan</article-title><source>Pathog Glob Health</source><year>2013</year><volume>107</volume><fpage>66</fpage><lpage>68</lpage><?supplied-pmid 23683332?><pub-id pub-id-type="pmid">23683332</pub-id></element-citation></ref><ref id="CR73"><label>73.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Khaskheli</surname><given-names>MN</given-names></name><name><surname>Baloch</surname><given-names>S</given-names></name><name><surname>Sheeba</surname><given-names>A</given-names></name><name><surname>Baloch</surname><given-names>S</given-names></name></person-group><article-title>Acute hepatitis E viral infection in pregnancy and maternal morbidity</article-title><source>J Coll Physicians Surg Pak</source><year>2015</year><volume>25</volume><fpage>734</fpage><lpage>737</lpage><?supplied-pmid 26454389?><pub-id pub-id-type="pmid">26454389</pub-id></element-citation></ref><ref id="CR74"><label>74.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kamar</surname><given-names>N</given-names></name><name><surname>Rostaing</surname><given-names>L</given-names></name><name><surname>Legrand-Abravanel</surname><given-names>F</given-names></name><name><surname>Izopet</surname><given-names>J</given-names></name></person-group><article-title>How should hepatitis E virus infection be defined in organ-transplant recipients?</article-title><source>Am J Transplant</source><year>2013</year><volume>13</volume><fpage>1935</fpage><lpage>1936</lpage><?supplied-pmid 23659713?><pub-id pub-id-type="pmid">23659713</pub-id></element-citation></ref><ref id="CR75"><label>75.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gerolami</surname><given-names>R</given-names></name><name><surname>Moal</surname><given-names>V</given-names></name><name><surname>Colson</surname><given-names>P</given-names></name></person-group><article-title>Chronic hepatitis E with cirrhosis in a kidney-transplant recipient</article-title><source>N Engl J Med</source><year>2008</year><volume>358</volume><fpage>859</fpage><lpage>860</lpage><?supplied-pmid 18287615?><pub-id pub-id-type="pmid">18287615</pub-id></element-citation></ref><ref id="CR76"><label>76.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>de Niet</surname><given-names>A</given-names></name><name><surname>Zaaijer</surname><given-names>HL</given-names></name><name><surname>ten Berge</surname><given-names>I</given-names></name><name><surname>Weegink</surname><given-names>CJ</given-names></name><name><surname>Reesink</surname><given-names>HW</given-names></name><name><surname>Beuers</surname><given-names>U</given-names></name></person-group><article-title>Chronic hepatitis E after solid organ transplantation</article-title><source>Neth J Med</source><year>2012</year><volume>70</volume><fpage>261</fpage><lpage>266</lpage><?supplied-pmid 22859417?><pub-id pub-id-type="pmid">22859417</pub-id></element-citation></ref><ref id="CR77"><label>77.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Haagsma</surname><given-names>EB</given-names></name><name><surname>van den Berg</surname><given-names>AP</given-names></name><name><surname>Porte</surname><given-names>RJ</given-names></name><name><surname>Benne</surname><given-names>CA</given-names></name><name><surname>Vennema</surname><given-names>H</given-names></name><name><surname>Reimerink</surname><given-names>JH</given-names></name><name><surname>Koopmans</surname><given-names>MP</given-names></name></person-group><article-title>Chronic hepatitis E virus infection in liver transplant recipients</article-title><source>Liver Transpl</source><year>2008</year><volume>14</volume><fpage>547</fpage><lpage>553</lpage><?supplied-pmid 18383084?><pub-id pub-id-type="pmid">18383084</pub-id></element-citation></ref><ref id="CR78"><label>78.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Renou</surname><given-names>C</given-names></name><name><surname>Lafeuillade</surname><given-names>A</given-names></name><name><surname>Cadranel</surname><given-names>JF</given-names></name><name><surname>Pavio</surname><given-names>N</given-names></name><name><surname>Pariente</surname><given-names>A</given-names></name><name><surname>Allegre</surname><given-names>T</given-names></name><name><surname>Poggi</surname><given-names>C</given-names></name><name><surname>Penaranda</surname><given-names>G</given-names></name><name><surname>Cordier</surname><given-names>F</given-names></name><name><surname>Nicand</surname><given-names>E</given-names></name></person-group><article-title>Hepatitis E virus in HIV-infected patients</article-title><source>AIDS</source><year>2010</year><volume>24</volume><fpage>1493</fpage><lpage>1499</lpage><?supplied-pmid 20467291?><pub-id pub-id-type="pmid">20467291</pub-id></element-citation></ref><ref id="CR79"><label>79.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dalton</surname><given-names>HR</given-names></name><name><surname>Bendall</surname><given-names>RP</given-names></name><name><surname>Keane</surname><given-names>FE</given-names></name><name><surname>Tedder</surname><given-names>RS</given-names></name><name><surname>Ijaz</surname><given-names>S</given-names></name></person-group><article-title>Persistent carriage of hepatitis E virus in patients with HIV infection</article-title><source>N Engl J Med</source><year>2009</year><volume>361</volume><fpage>1025</fpage><lpage>1027</lpage><?supplied-pmid 19726781?><pub-id pub-id-type="pmid">19726781</pub-id></element-citation></ref><ref id="CR80"><label>80.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Geng</surname><given-names>Y</given-names></name><name><surname>Zhang</surname><given-names>H</given-names></name><name><surname>Huang</surname><given-names>W</given-names></name><name><surname>Harrison</surname><given-names>TJ</given-names></name><name><surname>Geng</surname><given-names>K</given-names></name><name><surname>Li</surname><given-names>Z</given-names></name><name><surname>Wang</surname><given-names>Y</given-names></name></person-group><article-title>Persistent hepatitis e virus genotype 4 infection in a child with acute lymphoblastic leukemia</article-title><source>Hepat Mon</source><year>2014</year><volume>14</volume><fpage>e15618</fpage><?supplied-pmid 24596581?><pub-id pub-id-type="pmid">24596581</pub-id></element-citation></ref><ref id="CR81"><label>81.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gauss</surname><given-names>A</given-names></name><name><surname>Wenzel</surname><given-names>JJ</given-names></name><name><surname>Flechtenmacher</surname><given-names>C</given-names></name><name><surname>Navid</surname><given-names>MH</given-names></name><name><surname>Eisenbach</surname><given-names>C</given-names></name><name><surname>Jilg</surname><given-names>W</given-names></name><name><surname>Stremmel</surname><given-names>W</given-names></name><name><surname>Schnitzler</surname><given-names>P</given-names></name></person-group><article-title>Chronic hepatitis E virus infection in a patient with leukemia and elevated transaminases: a case report</article-title><source>J Med Case Rep</source><year>2012</year><volume>6</volume><fpage>334</fpage><?supplied-pmid 23031738?><pub-id pub-id-type="pmid">23031738</pub-id></element-citation></ref><ref id="CR82"><label>82.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tavitian</surname><given-names>S</given-names></name><name><surname>Peron</surname><given-names>JM</given-names></name><name><surname>Huynh</surname><given-names>A</given-names></name><name><surname>Mansuy</surname><given-names>JM</given-names></name><name><surname>Ysebaert</surname><given-names>L</given-names></name><name><surname>Huguet</surname><given-names>F</given-names></name><name><surname>Vinel</surname><given-names>JP</given-names></name><name><surname>Attal</surname><given-names>M</given-names></name><name><surname>Izopet</surname><given-names>J</given-names></name><name><surname>Recher</surname><given-names>C</given-names></name></person-group><article-title>Hepatitis E virus excretion can be prolonged in patients with hematological malignancies</article-title><source>J Clin Virol</source><year>2010</year><volume>49</volume><fpage>141</fpage><lpage>144</lpage><?supplied-pmid 20678959?><pub-id pub-id-type="pmid">20678959</pub-id></element-citation></ref><ref id="CR83"><label>83.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kamar</surname><given-names>N</given-names></name><name><surname>Selves</surname><given-names>J</given-names></name><name><surname>Mansuy</surname><given-names>JM</given-names></name><name><surname>Ouezzani</surname><given-names>L</given-names></name><name><surname>Peron</surname><given-names>JM</given-names></name><name><surname>Guitard</surname><given-names>J</given-names></name><name><surname>Cointault</surname><given-names>O</given-names></name><name><surname>Esposito</surname><given-names>L</given-names></name><name><surname>Abravanel</surname><given-names>F</given-names></name><name><surname>Danjoux</surname><given-names>M</given-names></name><etal/></person-group><article-title>Hepatitis E virus and chronic hepatitis in organ-transplant recipients</article-title><source>N Engl J Med</source><year>2008</year><volume>358</volume><fpage>811</fpage><lpage>817</lpage><?supplied-pmid 18287603?><pub-id pub-id-type="pmid">18287603</pub-id></element-citation></ref><ref id="CR84"><label>84.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lhomme</surname><given-names>S</given-names></name><name><surname>Marion</surname><given-names>O</given-names></name><name><surname>Abravanel</surname><given-names>F</given-names></name><name><surname>Izopet</surname><given-names>J</given-names></name><name><surname>Kamar</surname><given-names>N</given-names></name></person-group><article-title>Clinical manifestations, pathogenesis and treatment of hepatitis E virus infections</article-title><source>J Clin Med</source><year>2020</year><volume>9</volume><issue>2</issue><fpage>331</fpage></element-citation></ref><ref id="CR85"><label>85.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kamar</surname><given-names>N</given-names></name><name><surname>Mansuy</surname><given-names>JM</given-names></name><name><surname>Cointault</surname><given-names>O</given-names></name><name><surname>Selves</surname><given-names>J</given-names></name><name><surname>Abravanel</surname><given-names>F</given-names></name><name><surname>Danjoux</surname><given-names>M</given-names></name><name><surname>Otal</surname><given-names>P</given-names></name><name><surname>Esposito</surname><given-names>L</given-names></name><name><surname>Durand</surname><given-names>D</given-names></name><name><surname>Izopet</surname><given-names>J</given-names></name><name><surname>Rostaing</surname><given-names>L</given-names></name></person-group><article-title>Hepatitis E virus-related cirrhosis in kidney- and kidney-pancreas-transplant recipients</article-title><source>Am J Transplant</source><year>2008</year><volume>8</volume><fpage>1744</fpage><lpage>1748</lpage><?supplied-pmid 18557740?><pub-id pub-id-type="pmid">18557740</pub-id></element-citation></ref><ref id="CR86"><label>86.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lhomme</surname><given-names>S</given-names></name><name><surname>Marion</surname><given-names>O</given-names></name><name><surname>Abravanel</surname><given-names>F</given-names></name><name><surname>Chapuy-Regaud</surname><given-names>S</given-names></name><name><surname>Kamar</surname><given-names>N</given-names></name><name><surname>Izopet</surname><given-names>J</given-names></name></person-group><article-title>Hepatitis E pathogenesis</article-title><source>Viruses</source><year>2016</year><volume>8</volume><issue>8</issue><fpage>212</fpage></element-citation></ref><ref id="CR87"><label>87.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pischke</surname><given-names>S</given-names></name><name><surname>Hartl</surname><given-names>J</given-names></name><name><surname>Pas</surname><given-names>SD</given-names></name><name><surname>Lohse</surname><given-names>AW</given-names></name><name><surname>Jacobs</surname><given-names>BC</given-names></name><name><surname>Van der Eijk</surname><given-names>AA</given-names></name></person-group><article-title>Hepatitis E virus: infection beyond the liver?</article-title><source>J Hepatol</source><year>2017</year><volume>66</volume><fpage>1082</fpage><lpage>1095</lpage><?supplied-pmid 27913223?><pub-id pub-id-type="pmid">27913223</pub-id></element-citation></ref><ref id="CR88"><label>88.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kamar</surname><given-names>N</given-names></name><name><surname>Izopet</surname><given-names>J</given-names></name><name><surname>Pavio</surname><given-names>N</given-names></name><name><surname>Aggarwal</surname><given-names>R</given-names></name><name><surname>Labrique</surname><given-names>A</given-names></name><name><surname>Wedemeyer</surname><given-names>H</given-names></name><name><surname>Dalton</surname><given-names>HR</given-names></name></person-group><article-title>Hepatitis E virus infection</article-title><source>Nat Rev Dis Primers</source><year>2017</year><volume>3</volume><fpage>17086</fpage><?supplied-pmid 29154369?><pub-id pub-id-type="pmid">29154369</pub-id></element-citation></ref><ref id="CR89"><label>89.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dumoulin</surname><given-names>FL</given-names></name><name><surname>Liese</surname><given-names>H</given-names></name></person-group><article-title>Acute hepatitis E virus infection and autoimmune thyroiditis: yet another trigger?</article-title><source>BMJ Case Rep</source><year>2012</year><volume>2012</volume><fpage>bcr1220115441</fpage><?supplied-pmid 22604767?><pub-id pub-id-type="pmid">22604767</pub-id></element-citation></ref><ref id="CR90"><label>90.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fourquet</surname><given-names>E</given-names></name><name><surname>Mansuy</surname><given-names>JM</given-names></name><name><surname>Bureau</surname><given-names>C</given-names></name><name><surname>Recher</surname><given-names>C</given-names></name><name><surname>Vinel</surname><given-names>JP</given-names></name><name><surname>Izopet</surname><given-names>J</given-names></name><name><surname>Peron</surname><given-names>JM</given-names></name></person-group><article-title>Severe thrombocytopenia associated with acute autochthonous hepatitis E</article-title><source>J Clin Virol</source><year>2010</year><volume>48</volume><fpage>73</fpage><lpage>74</lpage><?supplied-pmid 20308017?><pub-id pub-id-type="pmid">20308017</pub-id></element-citation></ref><ref id="CR91"><label>91.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Deniel</surname><given-names>C</given-names></name><name><surname>Coton</surname><given-names>T</given-names></name><name><surname>Brardjanian</surname><given-names>S</given-names></name><name><surname>Guisset</surname><given-names>M</given-names></name><name><surname>Nicand</surname><given-names>E</given-names></name><name><surname>Simon</surname><given-names>F</given-names></name></person-group><article-title>Acute pancreatitis: a rare complication of acute hepatitis E</article-title><source>J Clin Virol</source><year>2011</year><volume>51</volume><fpage>202</fpage><lpage>204</lpage><?supplied-pmid 21628104?><pub-id pub-id-type="pmid">21628104</pub-id></element-citation></ref><ref id="CR92"><label>92.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Munoz-Suano</surname><given-names>A</given-names></name><name><surname>Hamilton</surname><given-names>AB</given-names></name><name><surname>Betz</surname><given-names>AG</given-names></name></person-group><article-title>Gimme shelter: the immune system during pregnancy</article-title><source>Immunol Rev</source><year>2011</year><volume>241</volume><fpage>20</fpage><lpage>38</lpage><?supplied-pmid 21488887?><pub-id pub-id-type="pmid">21488887</pub-id></element-citation></ref><ref id="CR93"><label>93.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kraus</surname><given-names>TA</given-names></name><name><surname>Engel</surname><given-names>SM</given-names></name><name><surname>Sperling</surname><given-names>RS</given-names></name><name><surname>Kellerman</surname><given-names>L</given-names></name><name><surname>Lo</surname><given-names>Y</given-names></name><name><surname>Wallenstein</surname><given-names>S</given-names></name><name><surname>Escribese</surname><given-names>MM</given-names></name><name><surname>Garrido</surname><given-names>JL</given-names></name><name><surname>Singh</surname><given-names>T</given-names></name><name><surname>Loubeau</surname><given-names>M</given-names></name><name><surname>Moran</surname><given-names>TM</given-names></name></person-group><article-title>Characterizing the pregnancy immune phenotype: results of the viral immunity and pregnancy (VIP) study</article-title><source>J Clin Immunol</source><year>2012</year><volume>32</volume><fpage>300</fpage><lpage>311</lpage><?supplied-pmid 22198680?><pub-id pub-id-type="pmid">22198680</pub-id></element-citation></ref><ref id="CR94"><label>94.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pazos</surname><given-names>M</given-names></name><name><surname>Sperling</surname><given-names>RS</given-names></name><name><surname>Moran</surname><given-names>TM</given-names></name><name><surname>Kraus</surname><given-names>TA</given-names></name></person-group><article-title>The influence of pregnancy on systemic immunity</article-title><source>Immunol Res</source><year>2012</year><volume>54</volume><fpage>254</fpage><lpage>261</lpage><?supplied-pmid 22447351?><pub-id pub-id-type="pmid">22447351</pub-id></element-citation></ref><ref id="CR95"><label>95.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zoller</surname><given-names>AL</given-names></name><name><surname>Schnell</surname><given-names>FJ</given-names></name><name><surname>Kersh</surname><given-names>GJ</given-names></name></person-group><article-title>Murine pregnancy leads to reduced proliferation of maternal thymocytes and decreased thymic emigration</article-title><source>Immunology</source><year>2007</year><volume>121</volume><fpage>207</fpage><lpage>215</lpage><?supplied-pmid 17250584?><pub-id pub-id-type="pmid">17250584</pub-id></element-citation></ref><ref id="CR96"><label>96.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kourtis</surname><given-names>AP</given-names></name><name><surname>Read</surname><given-names>JS</given-names></name><name><surname>Jamieson</surname><given-names>DJ</given-names></name></person-group><article-title>Pregnancy and infection</article-title><source>N Engl J Med</source><year>2014</year><volume>370</volume><fpage>2211</fpage><lpage>2218</lpage><?supplied-pmid 24897084?><pub-id pub-id-type="pmid">24897084</pub-id></element-citation></ref><ref id="CR97"><label>97.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sappenfield</surname><given-names>E</given-names></name><name><surname>Jamieson</surname><given-names>DJ</given-names></name><name><surname>Kourtis</surname><given-names>AP</given-names></name></person-group><article-title>Pregnancy and susceptibility to infectious diseases</article-title><source>Infect Dis Obstet Gynecol</source><year>2013</year><volume>2013</volume><fpage>752852</fpage><?supplied-pmid 23935259?><pub-id pub-id-type="pmid">23935259</pub-id></element-citation></ref><ref id="CR98"><label>98.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Saito</surname><given-names>S</given-names></name><name><surname>Nakashima</surname><given-names>A</given-names></name><name><surname>Shima</surname><given-names>T</given-names></name><name><surname>Ito</surname><given-names>M</given-names></name></person-group><article-title>Th1/Th2/Th17 and regulatory T-cell paradigm in pregnancy</article-title><source>Am J Reprod Immunol</source><year>2010</year><volume>63</volume><fpage>601</fpage><lpage>610</lpage><?supplied-pmid 20455873?><pub-id pub-id-type="pmid">20455873</pub-id></element-citation></ref><ref id="CR99"><label>99.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Akbar</surname><given-names>AN</given-names></name><name><surname>Vukmanovic-Stejic</surname><given-names>M</given-names></name><name><surname>Taams</surname><given-names>LS</given-names></name><name><surname>Macallan</surname><given-names>DC</given-names></name></person-group><article-title>The dynamic co-evolution of memory and regulatory CD4+ T cells in the periphery</article-title><source>Nat Rev Immunol</source><year>2007</year><volume>7</volume><fpage>231</fpage><lpage>237</lpage><?supplied-pmid 17318234?><pub-id pub-id-type="pmid">17318234</pub-id></element-citation></ref><ref id="CR100"><label>100.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sakaguchi</surname><given-names>S</given-names></name></person-group><article-title>Naturally arising Foxp3-expressing CD25+CD4+ regulatory T cells in immunological tolerance to self and non-self</article-title><source>Nat Immunol</source><year>2005</year><volume>6</volume><fpage>345</fpage><lpage>352</lpage><?supplied-pmid 15785760?><pub-id pub-id-type="pmid">15785760</pub-id></element-citation></ref><ref id="CR101"><label>101.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pal</surname><given-names>R</given-names></name><name><surname>Aggarwal</surname><given-names>R</given-names></name><name><surname>Naik</surname><given-names>SR</given-names></name><name><surname>Das</surname><given-names>V</given-names></name><name><surname>Das</surname><given-names>S</given-names></name><name><surname>Naik</surname><given-names>S</given-names></name></person-group><article-title>Immunological alterations in pregnant women with acute hepatitis E</article-title><source>J Gastroenterol Hepatol</source><year>2005</year><volume>20</volume><fpage>1094</fpage><lpage>1101</lpage><?supplied-pmid 15955220?><pub-id pub-id-type="pmid">15955220</pub-id></element-citation></ref><ref id="CR102"><label>102.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wedemeyer</surname><given-names>H</given-names></name><name><surname>Rybczynska</surname><given-names>J</given-names></name><name><surname>Pischke</surname><given-names>S</given-names></name><name><surname>Krawczynski</surname><given-names>K</given-names></name></person-group><article-title>Immunopathogenesis of hepatitis E virus infection</article-title><source>Semin Liver Dis</source><year>2013</year><volume>33</volume><fpage>71</fpage><lpage>78</lpage><?supplied-pmid 23564391?><pub-id pub-id-type="pmid">23564391</pub-id></element-citation></ref><ref id="CR103"><label>103.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Guidotti</surname><given-names>LG</given-names></name><name><surname>Chisari</surname><given-names>FV</given-names></name></person-group><article-title>Noncytolytic control of viral infections by the innate and adaptive immune response</article-title><source>Annu Rev Immunol</source><year>2001</year><volume>19</volume><fpage>65</fpage><lpage>91</lpage><?supplied-pmid 11244031?><pub-id pub-id-type="pmid">11244031</pub-id></element-citation></ref><ref id="CR104"><label>104.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jilani</surname><given-names>N</given-names></name><name><surname>Das</surname><given-names>BC</given-names></name><name><surname>Husain</surname><given-names>SA</given-names></name><name><surname>Baweja</surname><given-names>UK</given-names></name><name><surname>Chattopadhya</surname><given-names>D</given-names></name><name><surname>Gupta</surname><given-names>RK</given-names></name><name><surname>Sardana</surname><given-names>S</given-names></name><name><surname>Kar</surname><given-names>P</given-names></name></person-group><article-title>Hepatitis E virus infection and fulminant hepatic failure during pregnancy</article-title><source>J Gastroenterol Hepatol</source><year>2007</year><volume>22</volume><fpage>676</fpage><lpage>682</lpage><?supplied-pmid 17444855?><pub-id pub-id-type="pmid">17444855</pub-id></element-citation></ref><ref id="CR105"><label>105.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sehgal</surname><given-names>R</given-names></name><name><surname>Patra</surname><given-names>S</given-names></name><name><surname>David</surname><given-names>P</given-names></name><name><surname>Vyas</surname><given-names>A</given-names></name><name><surname>Khanam</surname><given-names>A</given-names></name><name><surname>Hissar</surname><given-names>S</given-names></name><name><surname>Gupta</surname><given-names>E</given-names></name><name><surname>Kumar</surname><given-names>G</given-names></name><name><surname>Kottilil</surname><given-names>S</given-names></name><name><surname>Maiwall</surname><given-names>R</given-names></name><etal/></person-group><article-title>Impaired monocyte-macrophage functions and defective toll-like receptor signaling in hepatitis E virus-infected pregnant women with acute liver failure</article-title><source>Hepatology</source><year>2015</year><volume>62</volume><fpage>1683</fpage><lpage>1696</lpage><?supplied-pmid 26331854?><pub-id pub-id-type="pmid">26331854</pub-id></element-citation></ref><ref id="CR106"><label>106.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Prusty</surname><given-names>BK</given-names></name><name><surname>Hedau</surname><given-names>S</given-names></name><name><surname>Singh</surname><given-names>A</given-names></name><name><surname>Kar</surname><given-names>P</given-names></name><name><surname>Das</surname><given-names>BC</given-names></name></person-group><article-title>Selective suppression of NF-kBp65 in hepatitis virus-infected pregnant women manifesting severe liver damage and high mortality</article-title><source>Mol Med</source><year>2007</year><volume>13</volume><fpage>518</fpage><lpage>526</lpage><?supplied-pmid 17660862?><pub-id pub-id-type="pmid">17660862</pub-id></element-citation></ref><ref id="CR107"><label>107.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kumar</surname><given-names>A</given-names></name><name><surname>Devi</surname><given-names>SG</given-names></name><name><surname>Kar</surname><given-names>P</given-names></name><name><surname>Agarwal</surname><given-names>S</given-names></name><name><surname>Husain</surname><given-names>SA</given-names></name><name><surname>Gupta</surname><given-names>RK</given-names></name><name><surname>Sharma</surname><given-names>S</given-names></name></person-group><article-title>Association of cytokines in hepatitis E with pregnancy outcome</article-title><source>Cytokine</source><year>2014</year><volume>65</volume><fpage>95</fpage><lpage>104</lpage><?supplied-pmid 24416783?><pub-id pub-id-type="pmid">24416783</pub-id></element-citation></ref><ref id="CR108"><label>108.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kmush</surname><given-names>BL</given-names></name><name><surname>Labrique</surname><given-names>A</given-names></name><name><surname>Li</surname><given-names>W</given-names></name><name><surname>Klein</surname><given-names>SL</given-names></name><name><surname>Schulze</surname><given-names>K</given-names></name><name><surname>Shaikh</surname><given-names>S</given-names></name><name><surname>Ali</surname><given-names>H</given-names></name><name><surname>Engle</surname><given-names>RE</given-names></name><name><surname>Wu</surname><given-names>L</given-names></name><name><surname>Purcell</surname><given-names>RH</given-names></name><etal/></person-group><article-title>The association of cytokines and micronutrients with hepatitis E virus infection during pregnancy and the postpartum period in rural Bangladesh</article-title><source>Am J Trop Med Hyg</source><year>2016</year><volume>94</volume><fpage>203</fpage><lpage>211</lpage><?supplied-pmid 26621563?><pub-id pub-id-type="pmid">26621563</pub-id></element-citation></ref><ref id="CR109"><label>109.</label><mixed-citation publication-type="other">Labrique AB, Klein S, Kmush B, Ali H, Engle R, Schulze K, Purcell R, West KP Jr, Nelson KE. Immunologic dysregulation and micronutrient deficiencies associated with risk of intrapartum hepatitis E infections in pregnant Bangladeshi women, vol. 26: Federation of American Societies for Experimental Biology; 2012. p. 127&#x02013;4. <ext-link ext-link-type="uri" xlink:href="https://www.fasebj.org/doi/10.1096/fasebj.26.1_supplement.127.4">https://www.fasebj.org/doi/10.1096/fasebj.26.1_supplement.127.4</ext-link>.</mixed-citation></ref><ref id="CR110"><label>110.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jiang</surname><given-names>T</given-names></name><name><surname>Christian</surname><given-names>P</given-names></name><name><surname>Khatry</surname><given-names>SK</given-names></name><name><surname>Wu</surname><given-names>L</given-names></name><name><surname>West</surname><given-names>KP</given-names><suffix>Jr</suffix></name></person-group><article-title>Micronutrient deficiencies in early pregnancy are common, concurrent, and vary by season among rural Nepali pregnant women</article-title><source>J Nutr</source><year>2005</year><volume>135</volume><fpage>1106</fpage><lpage>1112</lpage><?supplied-pmid 15867289?><pub-id pub-id-type="pmid">15867289</pub-id></element-citation></ref><ref id="CR111"><label>111.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Scholl</surname><given-names>PF</given-names></name><name><surname>Cole</surname><given-names>RN</given-names></name><name><surname>Ruczinski</surname><given-names>I</given-names></name><name><surname>Gucek</surname><given-names>M</given-names></name><name><surname>Diez</surname><given-names>R</given-names></name><name><surname>Rennie</surname><given-names>A</given-names></name><name><surname>Nathasingh</surname><given-names>C</given-names></name><name><surname>Schulze</surname><given-names>K</given-names></name><name><surname>Christian</surname><given-names>P</given-names></name><name><surname>Yager</surname><given-names>JD</given-names></name><etal/></person-group><article-title>Maternal serum proteome changes between the first and third trimester of pregnancy in rural southern Nepal</article-title><source>Placenta</source><year>2012</year><volume>33</volume><fpage>424</fpage><lpage>432</lpage><?supplied-pmid 22385826?><pub-id pub-id-type="pmid">22385826</pub-id></element-citation></ref><ref id="CR112"><label>112.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Navaneethan</surname><given-names>U</given-names></name><name><surname>Al Mohajer</surname><given-names>M</given-names></name><name><surname>Shata</surname><given-names>MT</given-names></name></person-group><article-title>Hepatitis E and pregnancy: understanding the pathogenesis</article-title><source>Liver Int</source><year>2008</year><volume>28</volume><fpage>1190</fpage><lpage>1199</lpage><?supplied-pmid 18662274?><pub-id pub-id-type="pmid">18662274</pub-id></element-citation></ref><ref id="CR113"><label>113.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Robinson</surname><given-names>DP</given-names></name><name><surname>Klein</surname><given-names>SL</given-names></name></person-group><article-title>Pregnancy and pregnancy-associated hormones alter immune responses and disease pathogenesis</article-title><source>Horm Behav</source><year>2012</year><volume>62</volume><fpage>263</fpage><lpage>271</lpage><?supplied-pmid 22406114?><pub-id pub-id-type="pmid">22406114</pub-id></element-citation></ref><ref id="CR114"><label>114.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yang</surname><given-names>C</given-names></name><name><surname>Yu</surname><given-names>W</given-names></name><name><surname>Bi</surname><given-names>Y</given-names></name><name><surname>Long</surname><given-names>F</given-names></name><name><surname>Li</surname><given-names>Y</given-names></name><name><surname>Wei</surname><given-names>D</given-names></name><name><surname>Hao</surname><given-names>X</given-names></name><name><surname>Situ</surname><given-names>J</given-names></name><name><surname>Zhao</surname><given-names>Y</given-names></name><name><surname>Huang</surname><given-names>F</given-names></name></person-group><article-title>Increased oestradiol in hepatitis E virus-infected pregnant women promotes viral replication</article-title><source>J Viral Hepat</source><year>2018</year><volume>25</volume><fpage>742</fpage><lpage>751</lpage><?supplied-pmid 29345855?><pub-id pub-id-type="pmid">29345855</pub-id></element-citation></ref><ref id="CR115"><label>115.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bi</surname><given-names>Y</given-names></name><name><surname>Yang</surname><given-names>C</given-names></name><name><surname>Yu</surname><given-names>W</given-names></name><name><surname>Zhao</surname><given-names>X</given-names></name><name><surname>Zhao</surname><given-names>C</given-names></name><name><surname>He</surname><given-names>Z</given-names></name><name><surname>Jing</surname><given-names>S</given-names></name><name><surname>Wang</surname><given-names>H</given-names></name><name><surname>Huang</surname><given-names>F</given-names></name></person-group><article-title>Pregnancy serum facilitates hepatitis E virus replication in vitro</article-title><source>J Gen Virol</source><year>2015</year><volume>96</volume><fpage>1055</fpage><lpage>1061</lpage><?supplied-pmid 25614592?><pub-id pub-id-type="pmid">25614592</pub-id></element-citation></ref><ref id="CR116"><label>116.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Singh</surname><given-names>S</given-names></name><name><surname>Daga</surname><given-names>MK</given-names></name><name><surname>Kumar</surname><given-names>A</given-names></name><name><surname>Husain</surname><given-names>SA</given-names></name><name><surname>Kar</surname><given-names>P</given-names></name></person-group><article-title>Role of oestrogen and its receptors in HEV-associated feto-maternal outcomes</article-title><source>Liver Int</source><year>2019</year><volume>39</volume><fpage>633</fpage><lpage>639</lpage><?supplied-pmid 29979823?><pub-id pub-id-type="pmid">29979823</pub-id></element-citation></ref><ref id="CR117"><label>117.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bose</surname><given-names>PD</given-names></name><name><surname>Das</surname><given-names>BC</given-names></name><name><surname>Kumar</surname><given-names>A</given-names></name><name><surname>Gondal</surname><given-names>R</given-names></name><name><surname>Kumar</surname><given-names>D</given-names></name><name><surname>Kar</surname><given-names>P</given-names></name></person-group><article-title>High viral load and deregulation of the progesterone receptor signaling pathway: association with hepatitis E-related poor pregnancy outcome</article-title><source>J Hepatol</source><year>2011</year><volume>54</volume><fpage>1107</fpage><lpage>1113</lpage><?supplied-pmid 21145845?><pub-id pub-id-type="pmid">21145845</pub-id></element-citation></ref><ref id="CR118"><label>118.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Andersson</surname><given-names>MI</given-names></name><name><surname>Hughes</surname><given-names>J</given-names></name><name><surname>Gordon</surname><given-names>FH</given-names></name><name><surname>Ijaz</surname><given-names>S</given-names></name><name><surname>Donati</surname><given-names>M</given-names></name></person-group><article-title>Of pigs and pregnancy</article-title><source>Lancet</source><year>2008</year><volume>372</volume><fpage>1192</fpage><?supplied-pmid 18926280?><pub-id pub-id-type="pmid">18926280</pub-id></element-citation></ref><ref id="CR119"><label>119.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Renou</surname><given-names>C</given-names></name><name><surname>Gobert</surname><given-names>V</given-names></name><name><surname>Locher</surname><given-names>C</given-names></name><name><surname>Moumen</surname><given-names>A</given-names></name><name><surname>Timbely</surname><given-names>O</given-names></name><name><surname>Savary</surname><given-names>J</given-names></name><name><surname>Roque-Afonso</surname><given-names>AM</given-names></name><collab>Association Nationale des Hepato-Gastroenterologues des Hopitaux G</collab></person-group><article-title>Prospective study of hepatitis E virus infection among pregnant women in France</article-title><source>Virol J</source><year>2014</year><volume>11</volume><fpage>68</fpage><?supplied-pmid 24716485?><pub-id pub-id-type="pmid">24716485</pub-id></element-citation></ref><ref id="CR120"><label>120.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gouilly</surname><given-names>J</given-names></name><name><surname>Chen</surname><given-names>Q</given-names></name><name><surname>Siewiera</surname><given-names>J</given-names></name><name><surname>Cartron</surname><given-names>G</given-names></name><name><surname>Levy</surname><given-names>C</given-names></name><name><surname>Dubois</surname><given-names>M</given-names></name><name><surname>Al-Daccak</surname><given-names>R</given-names></name><name><surname>Izopet</surname><given-names>J</given-names></name><name><surname>Jabrane-Ferrat</surname><given-names>N</given-names></name><name><surname>El Costa</surname><given-names>H</given-names></name></person-group><article-title>Genotype specific pathogenicity of hepatitis E virus at the human maternal-fetal interface</article-title><source>Nat Commun</source><year>2018</year><volume>9</volume><fpage>4748</fpage><?supplied-pmid 30420629?><pub-id pub-id-type="pmid">30420629</pub-id></element-citation></ref><ref id="CR121"><label>121.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>van Tong</surname><given-names>H</given-names></name><name><surname>Hoan</surname><given-names>NX</given-names></name><name><surname>Wang</surname><given-names>B</given-names></name><name><surname>Wedemeyer</surname><given-names>H</given-names></name><name><surname>Bock</surname><given-names>CT</given-names></name><name><surname>Velavan</surname><given-names>TP</given-names></name></person-group><article-title>Hepatitis E virus mutations: functional and clinical relevance</article-title><source>EBioMedicine</source><year>2016</year><volume>11</volume><fpage>31</fpage><lpage>42</lpage><?supplied-pmid 27528267?><pub-id pub-id-type="pmid">27528267</pub-id></element-citation></ref><ref id="CR122"><label>122.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Horvatits</surname><given-names>T</given-names></name><name><surname>Schulze Zur Wiesch</surname><given-names>J</given-names></name><name><surname>Lutgehetmann</surname><given-names>M</given-names></name><name><surname>Lohse</surname><given-names>AW</given-names></name><name><surname>Pischke</surname><given-names>S</given-names></name></person-group><article-title>The clinical perspective on hepatitis E</article-title><source>Viruses</source><year>2019</year><volume>11</volume><issue>7</issue><fpage>617</fpage></element-citation></ref><ref id="CR123"><label>123.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Debing</surname><given-names>Y</given-names></name><name><surname>Gisa</surname><given-names>A</given-names></name><name><surname>Dallmeier</surname><given-names>K</given-names></name><name><surname>Pischke</surname><given-names>S</given-names></name><name><surname>Bremer</surname><given-names>B</given-names></name><name><surname>Manns</surname><given-names>M</given-names></name><name><surname>Wedemeyer</surname><given-names>H</given-names></name><name><surname>Suneetha</surname><given-names>PV</given-names></name><name><surname>Neyts</surname><given-names>J</given-names></name></person-group><article-title>A mutation in the hepatitis E virus RNA polymerase promotes its replication and associates with ribavirin treatment failure in organ transplant recipients</article-title><source>Gastroenterology</source><year>2014</year><volume>147</volume><fpage>1008</fpage><lpage>1011.e1007</lpage><?supplied-pmid 25181691?><pub-id pub-id-type="pmid">25181691</pub-id></element-citation></ref><ref id="CR124"><label>124.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Borkakoti</surname><given-names>J</given-names></name><name><surname>Ahmed</surname><given-names>G</given-names></name><name><surname>Rai</surname><given-names>A</given-names></name><name><surname>Kar</surname><given-names>P</given-names></name></person-group><article-title>Report of novel H105R, D29N, V27A mutations in the methyltransferase region of the HEV genome in patients with acute liver failure</article-title><source>J Clin Virol</source><year>2017</year><volume>91</volume><fpage>1</fpage><lpage>4</lpage><?supplied-pmid 28359977?><pub-id pub-id-type="pmid">28359977</pub-id></element-citation></ref><ref id="CR125"><label>125.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Takahashi</surname><given-names>K</given-names></name><name><surname>Okamoto</surname><given-names>H</given-names></name><name><surname>Abe</surname><given-names>N</given-names></name><name><surname>Kawakami</surname><given-names>M</given-names></name><name><surname>Matsuda</surname><given-names>H</given-names></name><name><surname>Mochida</surname><given-names>S</given-names></name><name><surname>Sakugawa</surname><given-names>H</given-names></name><name><surname>Suginoshita</surname><given-names>Y</given-names></name><name><surname>Watanabe</surname><given-names>S</given-names></name><name><surname>Yamamoto</surname><given-names>K</given-names></name><etal/></person-group><article-title>Virulent strain of hepatitis E virus genotype 3, Japan</article-title><source>Emerg Infect Dis</source><year>2009</year><volume>15</volume><fpage>704</fpage><lpage>709</lpage><?supplied-pmid 19402955?><pub-id pub-id-type="pmid">19402955</pub-id></element-citation></ref><ref id="CR126"><label>126.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nan</surname><given-names>Y</given-names></name><name><surname>Yu</surname><given-names>Y</given-names></name><name><surname>Ma</surname><given-names>Z</given-names></name><name><surname>Khattar</surname><given-names>SK</given-names></name><name><surname>Fredericksen</surname><given-names>B</given-names></name><name><surname>Zhang</surname><given-names>YJ</given-names></name></person-group><article-title>Hepatitis E virus inhibits type I interferon induction by ORF1 products</article-title><source>J Virol</source><year>2014</year><volume>88</volume><fpage>11924</fpage><lpage>11932</lpage><?supplied-pmid 25100852?><pub-id pub-id-type="pmid">25100852</pub-id></element-citation></ref><ref id="CR127"><label>127.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ojha</surname><given-names>NK</given-names></name><name><surname>Lole</surname><given-names>KS</given-names></name></person-group><article-title>Hepatitis E virus ORF1 encoded macro domain protein interacts with light chain subunit of human ferritin and inhibits its secretion</article-title><source>Mol Cell Biochem</source><year>2016</year><volume>417</volume><fpage>75</fpage><lpage>85</lpage><?supplied-pmid 27170377?><pub-id pub-id-type="pmid">27170377</pub-id></element-citation></ref><ref id="CR128"><label>128.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lin</surname><given-names>S</given-names></name><name><surname>Yang</surname><given-names>Y</given-names></name><name><surname>Nan</surname><given-names>Y</given-names></name><name><surname>Ma</surname><given-names>Z</given-names></name><name><surname>Yang</surname><given-names>L</given-names></name><name><surname>Zhang</surname><given-names>YJ</given-names></name></person-group><article-title>The capsid protein of hepatitis E virus inhibits interferon induction via its N-terminal arginine-rich motif</article-title><source>Viruses</source><year>2019</year><volume>11</volume><issue>11</issue><fpage>1050</fpage></element-citation></ref><ref id="CR129"><label>129.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Surjit</surname><given-names>M</given-names></name><name><surname>Varshney</surname><given-names>B</given-names></name><name><surname>Lal</surname><given-names>SK</given-names></name></person-group><article-title>The ORF2 glycoprotein of hepatitis E virus inhibits cellular NF-kappaB activity by blocking ubiquitination mediated proteasomal degradation of IkappaBalpha in human hepatoma cells</article-title><source>BMC Biochem</source><year>2012</year><volume>13</volume><fpage>7</fpage><?supplied-pmid 22590978?><pub-id pub-id-type="pmid">22590978</pub-id></element-citation></ref><ref id="CR130"><label>130.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>John</surname><given-names>L</given-names></name><name><surname>Thomas</surname><given-names>S</given-names></name><name><surname>Herchenroder</surname><given-names>O</given-names></name><name><surname>Putzer</surname><given-names>BM</given-names></name><name><surname>Schaefer</surname><given-names>S</given-names></name></person-group><article-title>Hepatitis E virus ORF2 protein activates the pro-apoptotic gene CHOP and anti-apoptotic heat shock proteins</article-title><source>PLoS One</source><year>2011</year><volume>6</volume><fpage>e25378</fpage><?supplied-pmid 21966512?><pub-id pub-id-type="pmid">21966512</pub-id></element-citation></ref><ref id="CR131"><label>131.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Geng</surname><given-names>Y</given-names></name><name><surname>Yang</surname><given-names>J</given-names></name><name><surname>Huang</surname><given-names>W</given-names></name><name><surname>Harrison</surname><given-names>TJ</given-names></name><name><surname>Zhou</surname><given-names>Y</given-names></name><name><surname>Wen</surname><given-names>Z</given-names></name><name><surname>Wang</surname><given-names>Y</given-names></name></person-group><article-title>Virus host protein interaction network analysis reveals that the HEV ORF3 protein may interrupt the blood coagulation process</article-title><source>PLoS One</source><year>2013</year><volume>8</volume><fpage>e56320</fpage><?supplied-pmid 23418552?><pub-id pub-id-type="pmid">23418552</pub-id></element-citation></ref><ref id="CR132"><label>132.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Roberts</surname><given-names>SS</given-names></name><name><surname>Miller</surname><given-names>RK</given-names></name><name><surname>Jones</surname><given-names>JK</given-names></name><name><surname>Lindsay</surname><given-names>KL</given-names></name><name><surname>Greene</surname><given-names>MF</given-names></name><name><surname>Maddrey</surname><given-names>WC</given-names></name><name><surname>Williams</surname><given-names>IT</given-names></name><name><surname>Liu</surname><given-names>J</given-names></name><name><surname>Spiegel</surname><given-names>RJ</given-names></name></person-group><article-title>The ribavirin pregnancy registry: findings after 5 years of enrollment, 2003-2009</article-title><source>Birth Defects Res A Clin Mol Teratol</source><year>2010</year><volume>88</volume><fpage>551</fpage><lpage>559</lpage><?supplied-pmid 20564430?><pub-id pub-id-type="pmid">20564430</pub-id></element-citation></ref><ref id="CR133"><label>133.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Spera</surname><given-names>AM</given-names></name><name><surname>Eldin</surname><given-names>TK</given-names></name><name><surname>Tosone</surname><given-names>G</given-names></name><name><surname>Orlando</surname><given-names>R</given-names></name></person-group><article-title>Antiviral therapy for hepatitis C: has anything changed for pregnant/lactating women?</article-title><source>World J Hepatol</source><year>2016</year><volume>8</volume><fpage>557</fpage><lpage>565</lpage><?supplied-pmid 27134703?><pub-id pub-id-type="pmid">27134703</pub-id></element-citation></ref><ref id="CR134"><label>134.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dao Thi</surname><given-names>VL</given-names></name><name><surname>Debing</surname><given-names>Y</given-names></name><name><surname>Wu</surname><given-names>X</given-names></name><name><surname>Rice</surname><given-names>CM</given-names></name><name><surname>Neyts</surname><given-names>J</given-names></name><name><surname>Moradpour</surname><given-names>D</given-names></name><name><surname>Gouttenoire</surname><given-names>J</given-names></name></person-group><article-title>Sofosbuvir inhibits hepatitis E virus replication in vitro and results in an additive effect when combined with ribavirin</article-title><source>Gastroenterology</source><year>2016</year><volume>150</volume><fpage>82</fpage><lpage>85.e84</lpage><?supplied-pmid 26408347?><pub-id pub-id-type="pmid">26408347</pub-id></element-citation></ref><ref id="CR135"><label>135.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>van der Valk</surname><given-names>M</given-names></name><name><surname>Zaaijer</surname><given-names>HL</given-names></name><name><surname>Kater</surname><given-names>AP</given-names></name><name><surname>Schinkel</surname><given-names>J</given-names></name></person-group><article-title>Sofosbuvir shows antiviral activity in a patient with chronic hepatitis E virus infection</article-title><source>J Hepatol</source><year>2017</year><volume>66</volume><fpage>242</fpage><lpage>243</lpage><?supplied-pmid 27702641?><pub-id pub-id-type="pmid">27702641</pub-id></element-citation></ref><ref id="CR136"><label>136.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nishiyama</surname><given-names>T</given-names></name><name><surname>Kobayashi</surname><given-names>T</given-names></name><name><surname>Jirintai</surname><given-names>S</given-names></name><name><surname>Kii</surname><given-names>I</given-names></name><name><surname>Nagashima</surname><given-names>S</given-names></name><name><surname>Prathiwi Primadharsini</surname><given-names>P</given-names></name><name><surname>Nishizawa</surname><given-names>T</given-names></name><name><surname>Okamoto</surname><given-names>H</given-names></name></person-group><article-title>Screening of novel drugs for inhibiting hepatitis E virus replication</article-title><source>J Virol Methods</source><year>2019</year><volume>270</volume><fpage>1</fpage><lpage>11</lpage><?supplied-pmid 31004661?><pub-id pub-id-type="pmid">31004661</pub-id></element-citation></ref><ref id="CR137"><label>137.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Todt</surname><given-names>D</given-names></name><name><surname>Francois</surname><given-names>C</given-names></name><name><surname>Anggakusuma</surname></name><name><surname>Behrendt</surname><given-names>P</given-names></name><name><surname>Engelmann</surname><given-names>M</given-names></name><name><surname>Knegendorf</surname><given-names>L</given-names></name><name><surname>Vieyres</surname><given-names>G</given-names></name><name><surname>Wedemeyer</surname><given-names>H</given-names></name><name><surname>Hartmann</surname><given-names>R</given-names></name><name><surname>Pietschmann</surname><given-names>T</given-names></name><etal/></person-group><article-title>Antiviral activities of different interferon types and subtypes against Hepatitis E virus replication</article-title><source>Antimicrob Agents Chemother</source><year>2016</year><volume>60</volume><fpage>2132</fpage><lpage>2139</lpage><?supplied-pmid 26787701?><pub-id pub-id-type="pmid">26787701</pub-id></element-citation></ref><ref id="CR138"><label>138.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nan</surname><given-names>Y</given-names></name><name><surname>Ma</surname><given-names>Z</given-names></name><name><surname>Kannan</surname><given-names>H</given-names></name><name><surname>Stein</surname><given-names>DA</given-names></name><name><surname>Iversen</surname><given-names>PI</given-names></name><name><surname>Meng</surname><given-names>XJ</given-names></name><name><surname>Zhang</surname><given-names>YJ</given-names></name></person-group><article-title>Inhibition of hepatitis E virus replication by peptide-conjugated morpholino oligomers</article-title><source>Antivir Res</source><year>2015</year><volume>120</volume><fpage>134</fpage><lpage>139</lpage><?supplied-pmid 26086884?><pub-id pub-id-type="pmid">26086884</pub-id></element-citation></ref><ref id="CR139"><label>139.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Netzler</surname><given-names>NE</given-names></name><name><surname>Enosi Tuipulotu</surname><given-names>D</given-names></name><name><surname>Vasudevan</surname><given-names>SG</given-names></name><name><surname>Mackenzie</surname><given-names>JM</given-names></name><name><surname>White</surname><given-names>PA</given-names></name></person-group><article-title>Antiviral candidates for treating hepatitis E virus infection</article-title><source>Antimicrob Agents Chemother</source><year>2019</year><volume>63</volume><issue>6</issue><fpage>e00003</fpage><lpage>e00019</lpage><?supplied-pmid 30885901?><pub-id pub-id-type="pmid">30885901</pub-id></element-citation></ref><ref id="CR140"><label>140.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nishiyama</surname><given-names>T</given-names></name><name><surname>Kobayashi</surname><given-names>T</given-names></name><name><surname>Jirintai</surname><given-names>S</given-names></name><name><surname>Nagashima</surname><given-names>S</given-names></name><name><surname>Primadharsini</surname><given-names>PP</given-names></name><name><surname>Nishizawa</surname><given-names>T</given-names></name><name><surname>Okamoto</surname><given-names>H</given-names></name></person-group><article-title>Antiviral candidates against the hepatitis E virus (HEV) and their combinations inhibit HEV growth in in vitro</article-title><source>Antivir Res</source><year>2019</year><volume>170</volume><fpage>104570</fpage><?supplied-pmid 31362004?><pub-id pub-id-type="pmid">31362004</pub-id></element-citation></ref><ref id="CR141"><label>141.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rac</surname><given-names>MW</given-names></name><name><surname>Sheffield</surname><given-names>JS</given-names></name></person-group><article-title>Prevention and management of viral hepatitis in pregnancy</article-title><source>Obstet Gynecol Clin N Am</source><year>2014</year><volume>41</volume><fpage>573</fpage><lpage>592</lpage></element-citation></ref><ref id="CR142"><label>142.</label><element-citation publication-type="journal"><person-group person-group-type="author"><collab>European Association for the Study of the Liver</collab></person-group><article-title>Electronic address eee, European Association for the Study of the L: EASL clinical practice guidelines on hepatitis E virus infection</article-title><source>J Hepatol</source><year>2018</year><volume>68</volume><fpage>1256</fpage><lpage>1271</lpage><pub-id pub-id-type="pmid">29609832</pub-id></element-citation></ref><ref id="CR143"><label>143.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wu</surname><given-names>T</given-names></name><name><surname>Zhu</surname><given-names>FC</given-names></name><name><surname>Huang</surname><given-names>SJ</given-names></name><name><surname>Zhang</surname><given-names>XF</given-names></name><name><surname>Wang</surname><given-names>ZZ</given-names></name><name><surname>Zhang</surname><given-names>J</given-names></name><name><surname>Xia</surname><given-names>NS</given-names></name></person-group><article-title>Safety of the hepatitis E vaccine for pregnant women: a preliminary analysis</article-title><source>Hepatology</source><year>2012</year><volume>55</volume><fpage>2038</fpage><?supplied-pmid 22161542?><pub-id pub-id-type="pmid">22161542</pub-id></element-citation></ref><ref id="CR144"><label>144.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>M</given-names></name><name><surname>Li</surname><given-names>S</given-names></name><name><surname>He</surname><given-names>Q</given-names></name><name><surname>Liang</surname><given-names>Z</given-names></name><name><surname>Wang</surname><given-names>L</given-names></name><name><surname>Wang</surname><given-names>Q</given-names></name><name><surname>Wang</surname><given-names>L</given-names></name></person-group><article-title>Hepatitis E-related adverse pregnancy outcomes and their prevention by hepatitis E vaccine in a rabbit model</article-title><source>Emerg Microbes Infect</source><year>2019</year><volume>8</volume><fpage>1066</fpage><lpage>1075</lpage><?supplied-pmid 31339458?><pub-id pub-id-type="pmid">31339458</pub-id></element-citation></ref><ref id="CR145"><label>145.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zaman</surname><given-names>K</given-names></name><name><surname>Dudman</surname><given-names>S</given-names></name><name><surname>Stene-Johansen</surname><given-names>K</given-names></name><name><surname>Qadri</surname><given-names>F</given-names></name><name><surname>Yunus</surname><given-names>M</given-names></name><name><surname>Sandbu</surname><given-names>S</given-names></name><name><surname>Gurley</surname><given-names>ES</given-names></name><name><surname>Overbo</surname><given-names>J</given-names></name><name><surname>Julin</surname><given-names>CH</given-names></name><name><surname>Dembinski</surname><given-names>JL</given-names></name><etal/></person-group><article-title>HEV study protocol : design of a cluster-randomised, blinded trial to assess the safety, immunogenicity and effectiveness of the hepatitis E vaccine HEV 239 (Hecolin) in women of childbearing age in rural Bangladesh</article-title><source>BMJ Open</source><year>2020</year><volume>10</volume><fpage>e033702</fpage><?supplied-pmid 31959609?><pub-id pub-id-type="pmid">31959609</pub-id></element-citation></ref><ref id="CR146"><label>146.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>X</given-names></name><name><surname>Gong</surname><given-names>P</given-names></name><name><surname>Wagner</surname><given-names>AL</given-names></name><name><surname>Li</surname><given-names>Y</given-names></name><name><surname>Wang</surname><given-names>G</given-names></name><name><surname>Lu</surname><given-names>Y</given-names></name></person-group><article-title>Identification of hepatitis E virus subtype 4f in blood donors in Shanghai, China</article-title><source>Virus Res</source><year>2019</year><volume>265</volume><fpage>30</fpage><lpage>33</lpage><?supplied-pmid 30836112?><pub-id pub-id-type="pmid">30836112</pub-id></element-citation></ref></ref-list></back></article>